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Abstract 
 
PERCEIVED STRESS, SALIVARY CORTISOL, AND DEPRESSION IN ADULTS 
DIAGNOSED WITH POSTCONCUSSION SYNDROME: A PILOT STUDY  
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A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy from the School of Nursing at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2019. 
 
Director: Suzanne Ameringer, PhD, RN  
Professor, Department of Family and Community Health Nursing 
 
Introduction: Traumatic Brain Injury (TBI) affects approximately 1.7 million persons in 
the United States each year, of which an estimated 75% are categorized as mild TBI (mTBI). 
Most persons who experience an mTBI will recover completely, however an estimated 10% will 
develop Postconcussion Syndrome (PCS). PCS is chronic condition consisting of the presence of 
several coexisting symptoms that interfere with comfort and quality of life. Little is known 
regarding the development of PCS or the presence of PCS symptoms. Evidence supports a 
relationship between perceived stress, salivary cortisol levels, and depressive symptoms in 
persons after TBI; however, there are no known studies exploring these relationships in persons 
diagnosed with PCS. We sought to examine the relationships between perceived stress, salivary 
cortisol levels, and depressive symptoms in adult persons diagnosed with PCS; and to explore 
the potential mediating effect of cortisol between perceived stress and depressive symptoms. 
Method: A sample of 17 men and women diagnosed with PCS were recruited through general 
advertisement from Southwest Virginia and the Richmond area. Descriptive data collection 
included a Demographic Information form and the Rivermead Postconcussion Questionnaire. 
Variables of stress and depression were measured with the Perceived Stress Scale-10, Center for 
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Epidemiological Studies-Depression Scale and the PROMIS Emotional Distress (ED)- 
Depression Short form (SF). Salivary cortisol was collected with a SalivaBio Oral Swab (SOS) 
Saliva Collection System from Salimetrics. Data were analyzed with Wilcoxon Rank-Sum 
(Mann-Whitney U) test for continuous variables and Pearson’s Chi Square for categorical data. 
Spearman’s Rank Order Correlation Coefficients were used to compare variables for correlation. 
Results: We found a statistically significant relationship between stress and depression 
(Spearman rho=0.87; p <0.0001) in the study sample; however, we did not find a statistically 
significant relationship between stress and cortisol (Spearman rho=-0.11; p =0.6887) or 
depression and cortisol as measured by the CES-D (Spearman rho=-0.10; p=0.6989) and the 
PROMIS ED-Depression SF (Spearman rho= -0.40; p=0.1327). Conclusion: TBI is prevalent in 
the US with 75% of all occurrences being mild in severity. Although most individuals recover 
completely, every year approximately 10% of those with mTBI will develop the chronic 
symptoms of PCS. In this study, we found significant relationships between perceived stress and 
depression but not between cortisol and perceived stress nor between cortisol and depression. 
While perceived stress may impact the report of depressive symptoms in persons diagnosed with 
PCS, much is unknown about the influence of other factors such as stress, environment and 
social support, in the development of this syndrome or the influence of cortisol and other 
biologic markers such as pro- and anti-inflammatory cytokines and C-reactive protein. More 
research is needed to identify underlying psychoneurobiological mechanisms behind the 
development and presence of PCS and PCS symptoms in order to further inform our 
understanding of this condition, and to apprise the development of nursing interventions and self-
care strategies to enhance symptom management and improve quality of life for those who suffer 
with PCS. 
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Chapter I 
Introduction 
Traumatic Brain Injury (TBI) is estimated to affect approximately 1.7 million individuals 
in the United States each year; with those at highest risk being children under four years of age, 
teens between 15 and 19 years of age, and seniors greater than 65 years of age (Faul, Xu, Wald, 
& Coronado, 2010; Hoffman et al., 2010). TBI incidence is most commonly related to falls while 
TBI mortality is most commonly due to motor vehicle collisions (MVCs) (Faul et al., 2010; 
Hoffman et al., 2010). Diagnostically, TBI severity is classified as mild TBI (mTBI), moderate 
or severe. Severity of injury is determined by a combination of radiologic imaging, such as 
computed tomography (CT), magnetic resonance imaging (MRI), and neurological assessment 
(Valente & Fisher, 2011). Nationwide, approximately 75% of TBI is reported to be mild in 
severity, affecting approximately 600 of every 100,000 adults annually (Cassidy et al., 2004); 
making mTBI the prevailing diagnosis in the adult TBI population. 
Symptoms associated with mTBI may include difficulty concentrating, headache, and 
fatigue (Prigatano & Gale, 2011). Most individuals diagnosed with mTBI will recover 
completely with the resolution of any reported symptoms; however, nationally, approximately 
10% of patients who experience mTBI will continue to report symptoms, including distressed 
mood, > 6 months after injury (Prigatano & Gale, 2011). When symptoms persist for a prolonged 
period of time after injury, the individual may meet criteria for the diagnosis of postconcussion 
syndrome (PCS). 
Historically, PCS has been diagnosed in individuals with mTBI when symptoms, as 
described by the World Health Organization (WHO) (1992) have been present > 3 months. 
Currently, however, there are two sources used for diagnosing PCS: (1) the 10th edition of the 
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International Classification of Disease (ICD-10); and (2) the Diagnostic and Statistical Manual of 
Mental Disorders 5th Edition (DSM-V). The ICD-10 defines PCS as a syndrome that occurs 
after head injury and consists of a constellation of symptoms that may, or may not, co-occur. 
Symptoms may include headache, dizziness, fatigue, irritability, difficulty concentrating, and a 
reduced tolerance to physiological stress (WHO, 2015). The DSM-V does not have a definition 
for PCS. Instead, the DSM-V defines major or minor neurocognitive disorder (NCD) related to 
brain injury (American Psychiatric Association [APA], 2013). Criteria required to receive an 
NCD diagnosis, as described in the DSM-V, include the report of decline in cognitive function 
ranging from mildly concerning (mild) to severe enough to interfere with daily activity (major) 
(APA, 2013). NCD due to TBI is suspected when an individual presents with cognitive 
dysfunction and has a history of TBI. To meet diagnostic criteria, the TBI must have resulted in a 
loss of consciousness, inability to remember events surrounding the injury (i.e., amnesia), 
disorientation, confusion, and/or neurological signs; such as CT or MRI results indicating brain 
injury, new or worsening seizure disorder, and/or visual changes. These symptoms must present 
immediately after injury or immediately after return to consciousness and remain after the acute 
post-injury period (APA, 2013, p. 624). Symptoms such as irritability, anxiety, personality 
change, headache, fatigue, and sleep disturbance are described as supporting this diagnosis but 
are not required to meet diagnostic criteria (APA, 2013, p.625).  
Recent literature regarding PCS reflects diagnostic criteria per the DSM-IV-TR. 
According to the DSM-IV-TR, an individual is diagnosed with postconcussional disorder (PCD) 
if they have had a TBI and have experienced the presence of three or more co-occurring 
symptoms that may include headache, distressed mood, irritability, apathy, fatigue or sleep 
disturbances; persisting for three months or greater (APA, 2000). The benefit to the change in 
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ICD-10 diagnostic criteria is that more individuals who suffer persistent mTBI symptoms may 
receive treatment. The challenge to the DSM-V criteria is that potentially less treatment will be 
provided because the criteria for diagnosis relates to more severe symptomology of visual 
change and seizure. Thus, individuals who have been diagnosed with mTBI, but whose 
distressed mood or other symptoms have lasted longer than 3 months, may not meet the DSM-V 
criteria for PCS. Whether defined as PCS (DSM-IV-TR; ICD-10) or NCD (DSM-V), the 
persistent (i.e., more than 3 months) physical and psychological symptoms occurring after mTBI 
have been shown to negatively impact comfort and quality of life in this patient population 
(Emanuelson, Holmkvist, Björklund, & Stålhammar, 2003; Moran et al., 2012; Yeates et al., 
2012).  
Several factors have been implicated in the development of PCS following mTBI 
including psychosocial stress appraisal (or perception) and the physiological response to stress. 
Psychosocial stress refers to how an individual appraises or perceives their ability and resources 
to manage situations that may threaten well-being (Cohen, Kamarck, & Mermelstein, 1983; 
Lazarus & Folkman, 1984). Psychosocial stressors, such as an individual’s reported level of 
perceived stress, may have a role in the ultimate development and severity of the PCS symptom 
of distressed mood in the form of depression. For example, following mTBI, higher reports of 
perceived stress have been evidenced to correlate with greater reports of depression (Strom & 
Kosciulek, 2007). In a study conducted by Strom and Kosciulek (2007), data was collected on 
N=94 subjects with a history of mTBI. The authors reported the mean score for the 14-item 
Perceived Stress Scale (PSS) to be 28.8 with scores ranging from 10 to 50. The total score 
possible on the PSS ranges from 0 to 56, with higher scores indicating higher levels of perceived 
stress (Cohen et al., 1983). The reported mean depression score as measured by the Beck 
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Depression Inventory-2nd edition (Beck, Steer, & Brown, 1996) was 16.7 with participant scores 
ranging from 0 to 63. Total scores on the 21-item BDI range from 0 to 63. A score < 13 indicates 
no depression, a score of 14-19 indicates mild depression, a score of 20-28 indicates moderate 
depression, and scores > 29 indicate severe depression. The mean score of 16.7 identified by the 
researchers indicates that subjects in this study reported mild depression. Further, the researchers 
reported a statistically significant (β=0.67; p < 0.001) correlation between the levels of perceived 
stress and depression, with higher levels of perceived stress being predictive of higher levels of 
depressive symptoms (Strom & Kosciulek, 2007).  
In a study conducted by Bay, Hagerty, Williams, Kirsch, and Gillespie (2002), data on 
perceived stress and depressed mood was collected from N=75 subjects with mild (n=27) or 
moderate (n=48) brain injury (Bay et al., 2002; Bay, Sikorskii, & Gao, 2009). The researchers 
found subjects reported a mean score of 20.45 as collected on the Center for Epidemiological 
Studies Depression scale (CES-D) (Radloff, 1977), with 20% (n=15) reporting a score > 30.5. 
The CES-D is a measure of symptoms related to depressed mood with scores ranging from 0-60. 
A score of 16-20 indicates mild depression, 21-26 indicates moderate depression and a score 
greater than 27 indicates severe; thus, scores as reported by Bay et al. (2002) indicated symptoms 
ranged from mild to severe in this study population. In a secondary analysis examining the 
relationship between perceived stress and depressed mood in this same study population, Bay et 
al. (2009) reported a significantly positive relationship (β =0.51; p <0.01); showing that higher 
reports of perceived stress correlated with higher reports of depressive symptoms. These studies 
suggest a relationship between psychosocial or perceived stress and the potential development of 
depression in persons with mTBI. In addition to psychosocial stress, the physiological response 
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to stress (i.e. stress response) that occurs after mTBI is also related to the development of 
depressive symptoms in this population (Bay, Sikorskii, & Gao, 2009; Griesbach et al., 2011).  
TBI-related hypothalamic-pituitary-adrenal (HPA axis) dysfunction is thought to affect 
the response to acute and chronic stress. The physical stress response has been described as the 
neuroendocrine response to a psychosocial or physical stimulus or stressor (Chrousos & Gold, 
1992; Glaser & Keicolt-Glaser, 2005; Selye, 1950). This stress response occurs with activation 
of the HPA axis when a psychosocial or physical stressor is experienced. As a feedback response 
to a stressor, the hypothalamus secretes corticotropin releasing hormone (CRH). This in turn 
stimulates the pituitary gland to release adrenocorticotropic hormone (ACTH) leading to 
stimulation of the adrenal cortex and the release of corticosteroid hormones such as the 
glucocorticoid cortisol (Glaser & Kiecolt-Glaser, 2005; Selye, 1950). Research has demonstrated 
that this physical response to stress is altered after mTBI. For example, in rat models, Griesbach, 
Hovda, Tio, and Taylor (2011) identified an intensified response to acute stress after inducing 
mTBI, describing a higher than expected release of ACTH and less than expected corticosteroid 
levels after exposure to a stressor; indicating a dysfunction of this feedback mechanism related to 
mTBI. 
In humans, HPA axis dysfunction after moderate to severe TBI has been implicated in the 
development of mood disorders such as depression and anxiety (Bay et al., 2009). For example, 
Bay et al. (2002; 2009) examined the salivary cortisol data collected from N=75 subjects with 
mild or moderate TBI. Cortisol had been collected at 4 time points within 24 hours; 8 a.m., 12 
p.m., 4 p.m. and 8 p.m. Researchers reported summing the total cortisol count across time points 
and finding mean cortisol levels ranging from 0.17 to 0.89 nanograms per milliliter (ng/ml). 
Cortisol is released in a diurnal pattern, both naturally and when prompted in response to stress 
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(Kirschbaum & Hellhammer, 1989). Normal cortisol levels for a healthy adult may range from 
<0.50 to 42.8 nanomoles per liter (nM/L) with highest concentrations in the morning and lowest 
concentrations in the evening (Aardal & Holm, 1995). Converting the levels reported by Bay et 
al. (2009) from ng/ml to nM/L, demonstrated that the mean cortisol levels ranged from 0.47 to 
2.46 nM/L. Subjects’ cortisol levels demonstrated the presence of hypocortisolemia; one 
indicator of HPA axis dysfunction (Bay et al., 2009; Heim, Ehlert, & Hellhamer, 2000). Hypo- 
and hypercortisolemia are known to result from HPA axis dysfunction, and both have been 
associated with depression (Bay et al., 2009; Carroll et al., 2012; Jarcho, Slavich, Tylova-Stein, 
Wolkowitz, & Burke, 2013). The evidence presented by Bay et al. (2002; 2009) suggests a 
relationship between HPA axis dysfunction (i.e. hypocortisolemia) and depression after mild and 
moderate TBI.  
In summary, there is a burgeoning body of evidence suggests a relationship among 
perceived stress, HPA axis dysfunction as indicated by cortisol levels, and the symptom of 
depression in the mTBI and moderate TBI populations. However, to the best of our knowledge, 
research is limited and further, there are no known studies examining these relationships in 
persons diagnosed with PCS.  While there is limited data implicating cortisol as a factor in mTBI 
and PCS, HPA axis dysfunction has been implicated in the development of PCS symptoms such 
as depression. By examining the relationships among the variables of perceived stress scores, 
a.m. cortisol levels, and depression scores; we hoped to further elucidate underlying mechanisms 
of PCS symptoms. The current study provides a foundation for conducting future studies that 
may further our understanding of the development of PCS and PCS symptoms; studies that (a) 
addresses self-care strategies and symptom management, (b) contributes to evidence based 
practice, and (c) offer potential enhancement of patient comfort and quality of life. 
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Study Purpose 
The purpose of the current study was to examine and describe potential relationships 
among levels of perceived stress, biological indicators of stress (i.e., cortisol), and levels of 
depression in persons diagnosed with PCS. The primary aim was to examine potential 
relationships among levels of perceived stress, levels of cortisol, and symptoms of depression in 
adults diagnosed with PCS. The secondary aim was to examine the mediating effect of cortisol 
between perceived stress and symptoms of depression in persons diagnosed with PCS.  
Research Hypotheses 
Hypothesis 1: 
There is a correlation among levels of perceived stress, levels of cortisol, and depression   
in persons diagnosed with PCS 
Hypothesis 2: 
Cortisol mediates the relationship between levels of perceived stress and depression in 
persons diagnosed with PCS   
Therefore, the specific aims of the current study were to: 
1. Examine the relationships among perceived stress, salivary cortisol and symptoms of 
depression in persons diagnosed with PCS. 
2. Examine the mediating effect of cortisol between perceived stress and levels of 
depression in persons diagnosed with PCS. 
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Conceptual Framework 
The conceptual framework guiding the current study was adapted from the nursing 
framework of psychoneuroimmunology (PNI) (McCain, Gray, Walter, & Robins, 2005; Zeller, 
McCain, & Swanson, 1996). PNI, as a biobehavioral framework, is theoretically informed by the 
work of Selye (1950) and Ader (1981; 2000). Selye (1950; 1951) described a physiologic 
response to stress in his conceptual model of the General Adaptation Syndrome (GAS). This 
model posited that in defense of a physical stressor, the HPA axis is activated; resulting in the 
production of neuroendocrine hormones (i.e. CRH, ACTH, vasopressin, and cortisol). CRH 
stimulates the sympathetic nervous system (SNS) to release the catecholamines, epinephrine and 
norepinephrine, from the adrenal medulla. This neuroendocrine response is considered to be 
essential for adaptation and survival when exposed to a physical stressor (Selye, 1950). Ader 
(2000) founded the theory of PNI, which he defined as “the study of the interactions among 
behavior, neural and endocrine function, and immune system processes” (p. 167). One principle 
of this theory described a bi-directional pathway of communication between the brain and the 
neuroendocrine system; providing detail of a biobehavioral process whereby a psychosocial 
variable, such as perceived stress, may influence health outcomes (Ader, 2000). The primary 
objective of PNI research is to identify and describe relationships among stress, neuroendocrine 
and immune function, and health (Robinson, Mathews, & Witek-Janusek, 2002). When used as a 
framework for guiding nursing research, the PNI model supports nurse scientists in their efforts 
to explore and describe the multidimensional mechanisms of psychobehavioral and 
neuroendocrine system interactions. Within the PNI framework, the production and release of 
stress hormones such as cortisol is thought to be modulated by perceived stress; meaning that 
greater levels of perceived stress may contribute to HPA axis dysfunction as evidenced by hyper- 
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or hypocortisolemia (McCain et al., 2005). In the current study, the PNI framework was applied 
to explore potential relationships among levels of perceived stress, biological indicators of stress 
(i.e., cortisol), and levels of depression in persons diagnosed with PCS (see Appendix A).  
Study Significance 
This study has the potential to make a significant contribution to the literature in the areas 
of chronic illness and symptom management, nursing research, and to provide scientific evidence 
of relationships among biobehavioral variables in the PCS patient population. Findings from the 
current research study provide a description of relationships among perceived stress, levels of 
cortisol and depression in adults who are diagnosed with PCS. Study findings provide theoretical 
support for further research to inform our understanding of mechanisms related to the presence 
of PCS and PCS symptoms, and ultimately to support the development of symptom management 
strategies in this patient population. Chapter two contains a description of the conceptual 
framework and a review of the literature. 
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Chapter II 
Conceptual Framework and Literature Review  
The purpose of the current study was to examine and describe potential relationships 
between levels of perceived stress, biological indicators of stress (i.e., cortisol), and levels of 
depression in persons diagnosed with postconcussion syndrome (PCS). In chapter two, the 
conceptual framework of psychoneuroimmunology (PNI) is further explicated with a literature 
review related to the key variables of perceived stress, cortisol and depression. 
Psychoneuroimmunology as a Nursing Framework 
PNI is a biobehavioral framework integrated by McCain, Gray, Walter and Robins (2005) 
as a conceptual framework to guide nursing research related to mechanisms and processes 
surrounding symptoms and interventions for symptom management in a variety of chronic 
disease states including sickle cell disease (Ameringer, Elswick, & Smith, 2014), HIV (McCain 
et al., 2008), fibromyalgia (Menzies, Lyon, Elswick, McCain, & Gray, 2014), and 
cardiometabolic risk (Robins, Elswick, Sturgill, & McCain, 2015). The foundation of PNI is 
informed by the theoretical work of Selye (1950) and Ader (1981; 2000). Selye (1950; 1951) 
described the activation of the HPA axis in response to a physical stressor as part of the general 
adaptation syndrome (GAS) theory. According to PNI, exposure to a physical stressor may lead 
to an individual’s inability to physically adapt. The ongoing exposure to both acute and chronic 
stress creates a physiologic burden on the individual leading to compromised health status, 
placing the individual at risk for illness. Building on the work of Selye, Ader (2000) founded the 
PNI theory to more clearly describe the mechanisms of communication between and among the 
brain, neuroendocrine system and immune system. From this perspective, the PNI serves as a 
structure for the study of behavior, the neuroendocrine and immune systems, and the 
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bidirectional process of communication that occurs between or among systems. The implication 
of PNI theory is that psychosocial factors, such as perceived stress, stimulate the physical stress 
response thereby leading to disruption in levels of circulating stress hormones ultimately leading 
to changes in the inflammatory response (Ader, 2000; Kiecolt-Glaser, McGuire, Robles, & 
Glaser, 2002).  
The primary objective of nursing research based on PNI theory is to identify and describe 
biobehavioral relationships between psychological factors such as perceived stress and 
physiological indicators of neuroendocrine and immune function, and their potential impact on 
health and health outcomes (McCain et al., 2005; Starkweather, Witek-Janusek, & Mathews, 
2005). In that light, the PNI framework has been used to guide research to examine potential 
relationships among variables of stress and symptoms in a variety of patient populations. For 
example, in a cross-sectional correlational study, researchers examined the relationship among 
fatigue, pain, sleep, anxiety, depression, stress and biomarkers of inflammation and oxygenation 
in a sample of N=60 subjects between the ages of 15 and 30 years of age with sickle cell disease 
(Ameringer, Elswick & Smith, 2014). Fatigue was measured with three scales: The Brief Fatigue 
Inventory (BFI) (Mendoza et al., 1999); the Multidimensional Fatigue Symptom Inventory-Short 
Form (MFSI-SF) (Stein, Martin, Hann, & Jacobsen, 1998); and the PROMIS Fatigue Short Form 
(PROMIS, 2012). Stress was measured using the 10-item Perceived Stress Scale (PSS) (Cohen, 
Kamarch, & Mermelstein, 1983) and depression with the Center for Epidemiological Studies-
Depression scale (CES-D) (Radloff, 1977). The researchers noted a significant correlation 
between stress and fatigue as measured by the BFI (β=0.41; p <0.001), MFSI-SF (β=0.69; 
p<0.001) and PROMIS fatigue short form (β=0.41; p<0.01) indicating that higher reported levels 
of perceived stress correlated to higher reported levels of fatigue regardless of fatigue measure. 
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Additionally, the biomarker of hemoglobin was reported to correlate with fatigue as measured by 
PROMIS fatigue short form (β=-0.30; p<0.05). No findings were reported to describe a 
relationship between stress and depression in this study. 
In another PNI based exploratory study, researchers used a cross-sectional correlational 
design to examine the relationship among stress and symptoms of pain, fatigue, depression, 
functional status and biomarkers of inflammation in a sample of N=50 women with fibromyalgia 
(Menzies, Lyon, Elswick, Montpetit & McCain, 2013). Stress was measured with the 10-item 
PSS (Cohen, et al., 1983) and depression with the CES-D (Radloff, 1977). The researchers 
reported significant correlation between perceived stress and depression (β=0.80; p<0.01) 
meaning higher reported levels of perceived stress correlated to higher reported levels of 
depressive symptoms. Additionally, a significant correlation between perceived stress and the 
pro-inflammatory biomarker Interleukin (IL)-1β was reported (r=-0.29; p<0.05), suggesting a 
potential relationship may exist between the psychological variable of perceived stress and the 
immune system (Menzies et al., 2013).  
While these studies seem to substantiate the presence of a biobehavioral relationship 
among stress, biological indicators and symptoms in those experiencing a chronic illness, to our 
knowledge, there are no studies reporting the use of the PNI framework to examine a potential 
biobehavioral relationship among variables of stress, any biologic indicator, including cortisol, 
and depression in persons diagnosed with PCS.  
Conceptually, psychosocial or perceived stress, refers to how an individual interprets the 
ability and resources to manage situations that appear threatening (Cohen, Kamarck, & 
Mermelstein, 1983; Cohen, Kessler, & Gordon, 1997; Lazarus & Folkman, 1984). Physically, 
the perception of stress has been demonstrated to stimulate the hypothalamus (Glaser & Kiecolt-
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Glaser, 2005; Selye, 1950). This stimulation occurs as part of the GAS as described by Selye 
(1950; 1951). The end result of this process is the release of cortisol (Glaser & Kiecolt-Glaser, 
2005; Selye, 1950). Cortisol is a valid biological measure of HPA axis function and therefore, a 
valid measure of the response to stress (Heim & Nemeroff, 2002; Monroe, 2008). After mTBI, 
HPA axis function is theorized to be dysfunctional meaning that response to a stressor may result 
in a less than expected release of cortisol or hypocortisolemia (Griesbach, Hovda, Tio, &Taylor, 
2011). Both hypo- and hypercortisolemia are known to result from HPA axis dysfunction, and 
both have been associated with depression (Bay, Sikorskii, & Gao, 2009; Carroll et al., 2012; 
Jarcho, Slavich, Tylova-Stein, Wolkowitz, & Burke, 2013). Individuals diagnosed with PCS are 
at risk for the development of symptoms that include depression and when present, depressive 
symptoms have been shown to negatively impact overall quality of life (Emanuelson, Holmkvist, 
Björklund, & Stålhammar, 2003; Moran et al., 2012; Yeates et al., 2012). While the research 
literature has reported a relationship between stress and biopsychosocial outcomes in illnesses 
other than PCS (Ameringer, et al., 2014; Menzies, et al., 2013), and because there is a known 
relationship between hypo- or hypercortisolemia and depression (Jarcho et al., 2013); the risk to 
individuals diagnosed with PCS to develop a worsening of depressive symptoms or a diagnosis 
of clinical depression may be linked to levels of stress as well as to levels of the neuroendocrine 
biomarker, cortisol. Therefore, for purposes of the current study we used the PNI construct as a 
guide to examine potential relationships among three PNI-focused variables, i.e., the 
psychosocial factors of self-reported perceived stress and depression and the potential mediating 
effect of cortisol, in a sample of adults (aged >21 years) who have been diagnosed with PCS. 
Specifically, the primary relationships to be explored using the PNI framework were those that  
may exist between levels of perceived stress, cortisol and depressive symptoms in this 
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population. The secondary relationship to be examined was the potential influence of cortisol as 
a mediating variable between perceived stress and depressive symptoms in this population. Study 
results were anticipated to provide preliminary findings upon which future interventional 
research will be based.  
Literature Review 
The following literature review reflects the PNI framework that guided the current study. 
The literature was explored to identify evidence of relationships among perceived stress and 
cortisol; cortisol and depression; and perceived stress, cortisol, and depression in the PCS patient 
population. The electronic databases Cumulative Index of Nursing and Allied Health Literature 
(CINAHL), PsychINFO and PubMed were searched for articles published between 2005 and 
2016 using the initial keyword Postconcussion Syndrome. The search strategy included use of 
the additional key words perceived stress, cortisol, and depression, in each database to ensure 
identification of all available evidence. Inclusion criteria were those articles published in 
English, with a PCS population as subjects and included adults over age 18 years of age. 
Excluded were duplicates, dissertations, studies involving children, and those studies involving 
Post-traumatic Stress Disorder (PTSD). Additionally, the ancestry method was used, which 
involved reviewing the reference lists of articles that met inclusion criteria. Using the initial 
keyword (postconcussion syndrome) with variables of perceived stress, cortisol, and depression 
resulted in one research-related article; however, the study subjects were those with mild to 
moderate TBI rather than diagnosis of PCS (Bay & Xie, 2009). Thus, a secondary search using 
traumatic brain injury as a key word and the keywords of perceived stress, cortisol and 
depression, was completed in each database. A total of 6 articles were retrieved using this search 
strategy. After removing duplicates, a total of 29 articles were identified for review. After a 
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careful review of abstracts, a total of seven articles were found to meet inclusion criteria (See 
Appendix B, Table 1). 
Results 
Of the seven articles meeting inclusion criteria, two reported varied findings, using data 
from the same cross-sectional design parent study. The initial report of the parent study data 
examined perceived stress and depression in mTBI and moderate TBI but did not include the 
variable of cortisol (Bay, Hagerty, Williams, Kirsch & Gillespie, 2002). The second publication 
of the parent study reported findings related to perceived stress, cortisol and depression (Bay, 
Hagerty, Williams & Kirsch, 2005). The third and fourth articles selected for inclusion in this 
literature review included correlational studies; one, a longitudinal design examining potential 
relationship(s) between perceived stress and depression in subjects diagnosed with mTBI and 
moderate TBI (Bay & Donders, 2008); and the second, a cross-sectional design examining 
potential relationships between perceived stress and depression in subjects diagnosed with mTBI 
only (Strom & Kosciulek, 2007). Two further articles selected for review included quasi-
experimental longitudinal studies (Luo, Chai, Jiang, Chen, & Yan, 2015; Sung et al., 2016); each 
consisting of subjects with mTBI. The first study compared the effectiveness of interventions on 
symptoms of depression among three groups of subjects with mild, moderate and severe TBI 
(Luo et al., 2015), while the second study compared subjects with mTBI to a healthy control 
group (Sung et al., 2016). The final article for review was a randomized control trial (RCT) 
comparing a walking intervention to an attention control nutrition education intervention on 
perceived stress and depressive symptoms after TBI (Bellon et al., 2015). There were no studies 
found for the PCS patient population. Because PCS is a downstream diagnosis post mTBI, and 
because there was an absence of literature on our selected study population of PCS, we have 
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included research studies that examined our variables of interest; stress, cortisol, and depression 
in the TBI population (See Appendix B, Table 2). Following is further explication of the 
aforementioned studies.  
Bay et al. (2002) reported results of a cross-sectional study with a sample of N=75 
subjects with mild or moderate TBI. All participants had been hospitalized and diagnosed with 
either mTBI or moderate TBI at the time of their injury. Participants’ age range was not reported; 
however, the mean age was reported as 37.04 years. The sample consisted of n=39 men and 
n=36 women who were within 2-years of injury at the time of data collection. The authors 
reported on variables of post-injury perceived stress and depression. Post-injury stress was 
measured using the 14-item PSS (Cohen et al., 1983). PSS scores range from 0 to 56 on this 14-
item scale with higher scores indicating greater stress (Cohen et al., 1983). Depression was 
measured using the Neurobehavioral Functioning Inventory Depression sub-scale (NFI-D) 
(Kreutzer, Seel, & Marwitz, 1999; Seel & Kreutzer, 2003) and the CES-D (Radloff, 1977). The 
NFI-D is a 13-item scale with total scores ranging from 13 to 65; higher scores indicate greater 
depressive symptoms with risk for a diagnosis of depression at scores > 28 (Kreutzer, Seel, & 
Marwitz, 1999; Seel & Kreutzer, 2003). The CES-D is a measure of symptoms related to 
depressed mood with scores ranging from 0 to 60; higher scores indicate greater report of 
depressive symptoms (Radloff, 1977). A score of > 16 indicates potential for depression 
(Radloff, 1977). A significant relationship was found between stress, as measured by the PSS, 
and depression, as measured by the NFI-D, (R2=0.54, F=87.72 (1, 73), p=0.00), indicating that 
higher levels of perceived stress were positively correlated with higher levels of depressive 
symptoms. 
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The second report by Bay et al. (2005), included a study sample of N=75 subjects with 
mild or moderate TBI; ages ranging from 19 to 60 years of age with a mean age of 37.04 years. 
The authors expanded on prior analyses through inclusion of both pre- and post-injury perceived 
stress as well as salivary cortisol. Pre-injury stress was measured using the Childhood Adversity 
Checklist (CAC), a 16-item questionnaire was designed to capture chronic stress that may have 
occurred in childhood or be attributed to childhood events (Kupfer & Detre, 1974; Cohen, 
Coyne, & Duvall, 1993). As in the Bay et al. (2002) study, post-injury stress was measured using 
the 14-item PSS (Cohen et al., 1983) and depression was measured using the NFI-D (Kreutzer, et 
al., 1999; Seel & Kreutzer, 2003). For this study, salivary cortisol was reported as having been 
collected at four time points over a 24-hour time period (8:00 a.m., 12:00 p.m., 4:00 p.m. and 
8:00 p.m.) from n=53 of  N=75 (n=26 men and n=27 women) subjects; indicating missing data 
from n=22 subjects. There were no significant relationships between salivary cortisol and post-
injury stress or depressive symptoms; however, the authors reported that those individuals with 
mTBI had significantly (t= 2.66, df 48, p=0.011) greater 8:00 a.m. cortisol levels than those with 
moderate TBI. The authors did not discuss the significance of this difference between the two 
groups. The authors acknowledged the challenge of measuring cortisol in this population such as 
difficulty achieving 100% collection of all salivary cortisol specimens and self-report of 
compliance with collection protocol and stated the need for further research in this area. 
In a cross-sectional study conducted by Strom and Kosciulek (2007), researchers sought 
to explore the potential for a relationship among perceived stress, depression and coping in 
individuals post TBI by testing a theoretical model titled Stress, Appraisal and Coping (SAC) 
(Godfrey, Knight, & Partridge, 1996). The authors collected data from N=94 subjects, recruited 
from two rehabilitation centers, who had a confirmed diagnosis of TBI. Subjects’ ages ranged 
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from 18 to 74 years and included n=35 men and n=58 women. Perceived stress was measured 
using the 14-item PSS (Cohen et al., 1983) while depressive symptoms were measured using the 
Beck Depression Inventory 2nd edition (BDI-II) (Beck, Steer, & Brown, 1996). The BDI-II is a 
21-item scale with scores ranging from 0-63 with higher scores indicating greater report of 
depression (Beck et al., 1996). The authors reported PSS scores ranging from 10-50 with a mean 
score of 28.8 indicating subjects’ reported a moderate level of perceived stress. The reported 
mean depression score as measured by the BDI-II was 16.7 with participant scores ranging from 
0 to 63, indicating subjects in this study reported mild depression. Further, the researchers 
reported a statistically significant (β=0.67; p< 0.001) correlation between the levels of perceived 
stress scores and depression scores, with higher levels of perceived stress being predictive of 
higher levels of depressive symptoms. 
In a separate cross-sectional study, Bay and Donders (2008) explored the role of 
perceived stress in the development of depressive symptoms after TBI in a sample of N=84 
subjects recruited from eight rehabilitation centers. All participants had experienced prior 
hospitalization and had been diagnosed with either mTBI (n=65) or moderate TBI (n=19) at the 
time of their injury. Participants’ age range was not reported; however, the mean age was 
reported as 38.02 years. The sample consisted of n=43 men and n=41 women who were between 
one and 36 months from injury at the time of data collection. Chronic stress was measured using 
the 14-item PSS (Cohen, et al., 1983) and the Impact of Event Scale (IES) (Horowitz, Wilner, & 
Alvarez, 1979). The IES is a 15-item scale that measures the level of distress experienced by an 
individual when faced with an event perceived as stressful (Horowitz, et al., 1979). Scores from 
the IES range from 0 to 60 with higher scores indicating higher perceived stress (Horowitz, et al., 
1979). Depression was measured using the NFI-D (Kreutzer, et al., 1999; Seel & Kreutzer, 
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2003). The researchers also measured symptoms of pain and fatigue. Pain was measured using 
the McGill Pain Questionnaire Short Form (MPQ-SF) (Melzack, 1987). The MPQ-SF is a 15-
item questionnaire with scores ranged from 0 to 45, with higher scores indicating greater 
intensity of pain (Melzack, 1987). Fatigue was measured using the Modified Version of the 
Fatigue Impact Scale (MFIS) (Multiple Sclerosis Council for Clinical Practice Guidelines, 1998). 
The MFIS is a 21-item scale with scores ranging from 0-84 with higher scores indicating greater 
impact of fatigue (Multiple Sclerosis Council for Clinical Practice Guidelines, 1998). The 
authors reported subjects’ NFI-D scores ranged from 13-56 with a mean score of 31.71, noting 
that 58% (n=49) of subjects reported a score >28, indicating the presence of depressive 
symptoms and 42% (n=35) reported scores <28 indicating no depressive symptoms. For those 
subjects categorized as depressed (NFI-D score >28), the mean PSS score was 27.37. For those 
subjects categorized as not depressed (NFI-D <28), the mean PSS score was 19.66. This finding 
indicates that those subjects who reported depressive symptoms also reported higher levels of 
perceived stress when compared to those subjects who did not report depressive symptoms. No 
significant relationship was reported between levels of fatigue and depression or levels of pain 
and depression; however, levels of perceived stress were evidenced to explain levels of 
depression (R²=0.55) such that higher levels of perceived stress were more closely related to 
greater levels of depression. 
A report of a RCT study by Bellon et al. (2015) compared the effect of a 12-week 
walking intervention to a 12-week attention control nutrition education program on reported 
levels of perceived stress and depressive symptoms in subjects diagnosed with mild, moderate or 
severe TBI. Bellon et al recruited N=123 subjects with a history of diagnosed TBI from the 
community and from the Northern California TBI model Systems database. Perceived stress was 
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measured using the 14-item PSS (Cohen et al., 1983) and depression was measured using the 
CES-D (Radloff, 1977). Potential participants were screened to assess for eligibility and ability 
to ambulate. Once consented, subjects were randomized to either the walking intervention group 
or the nutrition education group. Measures were collected at baseline, 12- weeks, and 24- weeks. 
The walking intervention was practiced at the subjects’ home using a pedometer to track daily 
steps. The first week of the intervention, participants tracked their activity as usual. Each week 
after, the participants were asked to increase their steps by 5% until week- 8, at which time they 
were instructed to maintain the daily level of steps for weeks 9-12. Coaching was provided three 
times a week for weeks 1-3 then twice a week for weeks 4-8. Coaching was further reduced to 1- 
time a week for weeks 9-12. The nutrition education group served as a control group. 
Participants self-identified needed improvement in eating habits and were provided with 
nutritional education to meet their goals. Coaching was provided on the same schedule as the 
walking intervention group. At the completion of the intervention (week 12), measures were 
again collected. At this time, participants switched groups as part of the crossover design. At 24 
weeks, after completing the alternate intervention, measures were collected a final time. The 
authors reported that N=69 participants (n=41 men and n=28 women) completed the study. Study 
participants had a confirmed diagnosis of mild (n=10), moderate (n=10) or severe (n=35) TBI; 
n=13 subjects had a TBI diagnosis of unknown severity. The mean CES-D score was 16 for both 
groups at baseline, indicating mild depressive symptoms. At 12 weeks, the walking group 
reported a mean CES-D score of 12 as compared to the nutrition group, which reported a mean 
score of 15 indicating that the walking group had a decrease in report of depressive symptoms as 
compared to the nutrition group. At 24 weeks, both groups reported a mean CES-D score of 13, 
noted by the authors as a significant effect (p=0.007). The mean PSS scores at baseline were 25 
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for the walking group and 23 for the nutrition education group. At 12 weeks, the PSS mean score 
for the walking group had decreased to 20.76 whereas the mean for the nutrition education group 
had increased to 24.3. At completion of the study, the 24th week, the PSS mean score for both 
groups were reported as 21. The authors reported significant decreases in PSS scores during the 
walking intervention for both groups (p=0.006) with a significant decrease in PSS score at 24 
weeks for both groups (p=0.006). This indicates that the 12-week walking intervention was 
effective in reducing scores on both the PSS and the CES-D. 
In a quasi-experimental repeated measures study, exploring the effect of cortisol 
supplementation, psychotherapy and Citalopram on depressive symptoms after TBI; Luo, Chai, 
Jiang, Chen, & Yan (2015) reported on N=68 subjects diagnosed with depression after TBI. 
Participants were recruited at the first follow up appointment after discharge from the hospital 
post injury. The sample consisted of n=45 men and n=23 women ranging in age from 18 to 70 
years. Demographic data did not include the number of participants in each category of TBI; 
mild, moderate or severe. The study protocol consisted of initial measurement of depressive 
symptoms using the BDI-II (Beck et al., 1996) at which time subjects began the initial treatment 
with psychotherapy. The authors reported n=22 subjects reported mild depression, n=37 reported 
moderate depression, and n=9 subjects reported severe depression at baseline prior to treatment 
with psychotherapy. The psychotherapy intervention consisted of one-hour sessions each week 
for six weeks for all subjects. At the conclusion of psychotherapy, subjects were again assessed 
for depressive symptoms using the BDI-II. The authors reported that n=8 subjects were found to 
report few to no depressive symptoms or a score of <13 as collected on the BDI-II. The 
remaining n=60 subjects were then assessed for hypocortisolemia and assigned to be in one of 
two treatment groups based on their individual serum cortisol levels. Participants found to have 
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hypocortisolemia (n=32) were placed in a group receiving psychotherapy plus the administration 
of two medications (i.e. the antidepressant medication Citalopram and Prednisone); those with 
normal cortisol levels (n=28) were placed in a group receiving psychotherapy and only one 
medication (i.e. Citalopram). A limitation to understanding this study lies in the fact that while 
cortisol levels were reportedly measured, specific levels were not reported. After three weeks of 
treatment, each group was assessed for depressive symptoms for a third time and all but one 
study participant in the normal cortisol level group demonstrated a decrease in depressive 
symptoms after treatment. Additionally, all but two study participants in the hypocortisolemia 
group, who received both Citalopram and Prednisone, reported a decrease in depressive 
symptoms after treatment. It was not reported whether cortisol levels were re-evaluated post-
treatment. While data on the number of participants at each level of injury was not reported, 
study outcomes, as reported by Luo et al. (2015), demonstrated no significant relationship 
between severity of injury and severity of depression (r=0.128, p>0.05). Such findings suggest 
that those individuals with mTBI are just as likely to develop depressive symptoms as those with 
moderate or severe TBI.  
Using a quasi-experimental design with two data collection time points, Sung et al. 
(2016), reported on heart rate variability (HRV), neuroendocrine function, and symptoms of 
anxiety and depression in a study comparing N=483 subjects with mTBI (n=331) to a healthy 
control group (n=152). Participants were recruited through two University hospitals. The mTBI 
group inclusion criteria required diagnosis of mTBI with a negative computed tomography scan 
of the brain. The healthy control group inclusion criteria required no history of TBI. Both groups 
included subjects > 20 years of age. Neuroendocrine hormones, including cortisol, were 
collected from serum. Depression was measured with the BDI-II (Beck et al., 1996). In addition, 
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the researchers measured heart rate variability (HRV), a measure of autonomic nervous system 
(ANS) function with ANS dysfunction suggested to be related to mood disorder such as 
depression and anxiety (Appelhans & Luecken, 2006; Zheng & Moritani, 2008). All measures 
were collected at baseline and 6 weeks. Mean age of participants was reported as 27.5 years in 
the control group and 40 years in the mTBI group; age ranges were not reported. Median values 
of cortisol were reported as 10.88 µg/dL in the healthy control group compared to a median of 
10.66 µg/dL in the mTBI group at week 1, with no significant difference in cortisol levels 
between groups (p=0.698). The authors reported that although cortisol levels in the mTBI group 
decreased from 10.66 µg/dL in week 1 to 9.65 µg/dL in week 6, this change was not significant. 
The authors reported finding significantly greater levels of depression in the mTBI group as 
compared to the healthy control group at weeks 1 (p=0.002) and 6 (p<0.001). There was no 
reported data suggesting statistical analysis was completed to examine correlations between 
cortisol and depression in this study. 
Discussion 
Initial review of the literature to identify studies examining a biobehavioral relationship 
among the variables of perceived stress, cortisol and depression in individuals diagnosed with 
PCS revealed no studies in the PCS population. Given the relationship between mTBI and PCS, 
the search was expanded to include the larger TBI population, ultimately yielding seven studies.  
TBI affects approximately 1.7 million people in the United States (U.S.) each year, 
approximately 75% of which are categorized as mild. Therefore, it may be concluded that 
approximately 1.3 million people incur mTBI annually (Centers for Disease Control and 
Prevention [CDC], 2003; Coronado et al., 2011). Most people who sustain a mTBI will recover 
completely; however, as many as 10%  will continue to experience symptoms such as pain, 
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fatigue and depression three-months after injury leading to the potential for a diagnosis of PCS 
(Cicerone & Kalmar, 1995; Packard, 2008).  
The pathophysiology underlying the trajectory from acute injury to mTBI and the 
development of PCS remains unclear. One potential mechanism is HPA axis dysfunction related 
to brain injury (Griesbach et al., 2011; McAllistar, 2011). The HPA axis is activated in response 
to psychosocial and physical stressors triggering the release of neuroendocrine hormones, 
particularly cortisol (Glaser & Kiecolt-Glaser, 2005; Selye, 1950). HPA axis dysfunction 
presents as either an underactive response to stress with too little cortisol release (hypo-
cortisolemia), or an overactive response to stress with too much cortisol release (hyper-
cortisolemia) (Tsigos & Chrousos, 2002). While non-biologic factors that may contribute to PCS 
remain unclear, an emerging body of evidence indicates relationships among perceived stress 
and a history of depression or anxiety may explain its development (Meares et al., 2008; 
Ponsford et al., 2012). For example, individuals diagnosed with mTBI, moderate or severe TBI, 
who reported higher levels of perceived stress also reported greater levels of depression (Bay & 
Donders, 2008; Bay et al., 2002; Bay et al., 2005; Bellon et al., 2015; Strom & Kosciulek, 2007). 
Given that perceived stress has been consistently associated with an increased risk for depression 
in these patient populations, perceived stress may also affect the trajectory of PCS. 
While the studies revealed in the literature review have included participants with varying 
degrees of TBI, which are antecedents to PCS, no study was found to have included subjects who 
have been diagnosed with PCS. We suggest that the absence of inclusion of study participants 
with PCS is a gap in the science that the current study sought to address. Other considerations 
related to outcomes of this literature review included an examination and comparison of 
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measures used to capture the non-biological variables of stress and depression, and the biological 
measure of cortisol.  
Measures: Non-biological 
The method of measurement for perceived stress was consistent across the studies 
reviewed, in that five of the seven studies exploring a relationship between perceived stress and 
depression measured perceived stress using either the 10-item or 14-item PSS (Bay & Donders, 
2008; Bay et al., 2002; Bay et al., 2005; Bellon et al., 2015; Strom & Kosciulek, 2007). The PSS 
is a valid and reliable measure of perceived stress with little time burden for participants. While 
there was some consistency, studies varied on how depression was measured. One author 
reported using both the CES-D and the NFI-D to measure depression (Bay et al., 2002), whereas 
two authors reported using only the NFI-D (Bay & Donder, 2008; Bay et al., 2005). One author 
reported levels of depression as collected using only the CES-D (Bellon et al., 2015). The 
remaining authors reported levels of depression as collected using the BDI-II (Luo et al., 2015; 
Strom & Kosciulek, 2007; Sung et al., 2016). Although the NFI-D was designed for neurologic 
populations, the CES-D was found to significantly correlate with the NFI-D (Bay et al., 2002). 
The CES-D, developed for use in the general population, is a measure of symptoms listed in the 
DSM-V as being related to depressed mood but is not a diagnostic tool. This measure is sensitive 
to the presence of potentially impactful depressive symptoms even in the absence of clinical 
depression (Radloff, 1977; Bay, Hagerty, & Williams, 2007). Both the CES-D and the NFI-D are 
brief thus limiting participant burden. While the CES-D, the NFI-D and the BDI-II are valid and 
reliable measures, only the NFI-D is designed specifically for use in the neurologic population.  
Variation in measures complicates comparison of results in this population. The use of 
appropriate, common measures move the science forward. A Common Data Element (CDE) 
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initiative promoted by the National Institute of Health (NIH) was launched to identify a common 
set of measures to better organize and improve the communication of research findings (NIH, 
2016). As part of this initiative, the NIH developed a CDE portal 
(https://www.nlm.nih.gov/cde/summary_table_1.html) that provides a link to several resources 
reflecting the current drive to operationalize standardization of measures across patient 
populations. Among these are the NIH Toolbox for assessment of neurologic and behavioral 
function as well as the National Institute of Neurological Disorder and Stroke (NINDS) CDE 
(NIH, 2016). When reviewing these resources for standardized measures of perceived stress and 
depression, a comparative review can be made regarding CDE suggested measures and those 
measures used in the reviewed studies. For example, the CES-D and BDI-II, though not 
developed specifically for the neurologic population, are recommended for use in the TBI 
population as a supplemental measure of depression (NINDS, 2016); Therefore, it would be 
appropriate to administer these instruments to the PCS patient population. The NIH Toolbox, as 
accessed through the CDE portal, contains another of the variables of interest in our current 
study, perceived stress. The standardized instrument suggest by the NIH toolbox is identified as 
the 10-item perceived stress survey with items taken from the PSS (NIH & Northwestern 
University, 2012). Upon further examination of these resources, it was found that the use of these 
standardized instruments is not always free to the public. There are reported fees attached to use, 
therefore while inclusion of CDE standardized measures would enhance potential contributions 
from the current study to the science of PCS research, because of the pilot nature of this project 
as a first step in the research trajectory, funding for such measures was not available. Therefore, 
based on TBI research indicating correlation of the CES-D with the NFI-D (Radloff, 1977), and 
CDE support of the 10-item PSS (Cohen, Kamarck, & Mermelstein, 1983), we designed a 
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descriptive study using these measures to advance the science and collected measurement of 
perceived stress with the 10-item PSS and depression using the CES-D.  
Measures: Biological 
The measurement of cortisol was included as a variable in three studies, all of which 
identified the presence of hypocortisolemia in a portion of study participants (Bay et al., 2005; 
Luo et al., 205; Sung et al., 2016). There were inconsistencies, however, in both the collection 
methods and reporting of cortisol among these studies. The medium of collection differed 
between the studies with one collecting salivary cortisol (Bay et al., 2005) and two collecting 
serum cortisol (Luo et al., 2015; Sung et al., 2016). The collection of salivary cortisol has the 
advantages of being non-invasive, easily collected by the subject in their home, and 
demonstrating less potential for causing a stress induced rise in cortisol (Aardal & Holm, 1995). 
Additionally, when comparing measurement of cortisol collected from saliva and serum, 
reference ranges or normal values are closely correlated (Aardal & Holm, 1995).  
A limitation among the studies was a lack of standardized reporting of concentration 
solution units of cortisol. For example, Bay et al. (2005) reported cortisol units in nanograms per 
milliliter (ng/mL), Sung et al. (2016) reported cortisol units in micrograms per deciliter (µg/dL), 
and Luo et al. (2015) reported measuring cortisol but did not report concentration solution units. 
Normal cortisol values for a healthy adult, whether measured in saliva or serum, have been 
described as ranging from <0.50 to 42.8 nanomoles per liter (nM/L) with highest concentrations 
in the morning and lowest concentrations in the evening (Aardal & Holm, 1995). For example, 
Aardal and Holm (1995) reported a normal mean value of salivary cortisol in a healthy adult to 
be 11.9 nM/L at 8:00 a.m. and 1.8 nM/L at 10:00 p.m. and an equivalent normal serum cortisol 
to be 15.5 nM/L at 8:00 a.m. and 3.9 nM/L. Converting the salivary cortisol levels reported by 
28 
 
 
Bay et al. (2005) from ng/mL to nM/L demonstrated, therefore, that the mean cortisol levels in 
their study ranged from 0.47 to 2.46 nM/L with a mean value of 1.63 nM/L (0.59 ng/mL) 
collected at 8:00 a.m. and a mean value of 0.47 nM/L (0.17 ng/mL) collected at 8:00 p.m. This 
suggests underactive HPA axis function in response to stress as evidenced by hypo-cortisolemia 
in this study population. Both hypo- and hypercortisolemia are known to result from HPA axis 
dysfunction, and both have been associated with depression (Bay, Sikorskii, & Gao, 2009; 
Carroll et al., 2012; Jarcho, Slavich, Tylova-Stein, Wolkowitz, & Burke, 2013). 
Luo et al. (2015) did not report cortisol levels, only using serum cortisol to stratify 
subjects into groups, i.e. a normal cortisol value group and a hypo-cortisolemia group. Sung et al. 
(2016) reported a normal serum cortisol reference range of 5-23 µg/dL for their study, with mean 
cortisol levels found to be 10.88 µg/dL in the healthy control group and 10.66 µg/dL in the 
mTBI group at week 1. The cortisol level in the mTBI group decreased to a mean 9.65 µg/dL in 
week 6. The decrease in cortisol level in the mTBI group from week 1 to week 6 was noted to 
not be significant. The authors did not report the hour of collection, only that collection occurred 
at two time points, week 1 and week 6 and no comparison was made between cortisol and 
depression; therefore, it is not possible to determine the significance of their study findings. 
When considering future studies in which cortisol is a variable of interest, such as in the current 
study, it will be important to thoughtfully consider methods of cortisol sampling including the 
data collection period and the type of medium used to collect cortisol samples, as well as include 
reporting of normal reference ranges and consider standardization of concentration units.  
Overall, findings from this literature review have contributed to the design and methods 
of the current study. Prior research has elucidated both the strengths and limitations of the 
biologic indicator discussed regarding cortisol. The strengths include supporting the collection of 
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cortisol, a valid and reliable method of measuring this biological indicator of stress (Aardal & 
Holm, 1995; Kirschbaum & Hellhammer, 1989; Laudat et al., 1988), thus we included cortisol 
not only as a mediator between stress and depression, but we also examined it as the classic 
biologic measure of HPA axis dysfunction. Weaknesses include the identification of 
discrepancies among the types of medium selected for cortisol collection (i.e. saliva or serum). 
An additional weakness or limitation were the variation of reported concentration solution units 
(ng/mL and µg/dL). Both limitations challenge an accurate interpretation of collective study 
findings. We addressed these limitations in the current study by reporting normal cortisol levels, 
comparing study findings against these standardized levels and exploring appropriate laboratory 
resources to address the most commonly used product related to standardized salivary cortisol 
collection. 
In summary, this literature review demonstrated that the relationships between perceived 
stress and cortisol, as well as those between perceived stress and depression have been examined 
in the TBI patient population. Despite examination of relationships between these variables, 
there remains a gap in the literature of studies incorporating the variables of perceived stress, 
cortisol and depression in the PCS population. In that light, we proposed to study the 
relationships between perceived stress and depression, perceived stress and cortisol including 
examination of cortisol as a mediating variable. This research provides pilot data on which to 
build further studies exploring biobehavioral mechanisms behind the presence of PCS and PCS 
symptoms, building to a program of interventional research. Given the symptom burden in 
individuals living with PCS and the evidence that perceived stress levels and depressive 
symptoms can be reduced with mind-body interventions such as guided imagery (Menzies et al., 
2014) and tai chi (Robins et al., 2013), development of similar interventions are reasonable to 
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decrease symptoms in this patient population. Before such assistance can be offered to the PCS 
population; however, it is important to first examine and describe the presence of perceived 
stress and its relationship to depression in this patient population while also considering any 
contributions that may or may not be attributed to the neuroendocrine hormone, cortisol. In 
chapter three, the study methodology and design are described. 
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Chapter III  
Research Design and Methods 
A review of the literature resulted in few studies investigating the relationships among 
stress, cortisol and depression in the mild traumatic brain injury (mTBI) population. To date, we 
know of no studies examining potential relationships between these variables in adults diagnosed 
with post-concussion syndrome (PCS). In chapter three, we present the research methodology for 
the pilot study examining these relationships in adults with PCS. 
Study Design 
This was a descriptive, cross-sectional design to examine and describe relationships 
among levels of perceived stress and cortisol, cortisol and depressive symptoms, and perceived 
stress and depressive symptoms in persons diagnosed with PCS. The research questions 
addressed in this study were:  
1. Is there a relationship among levels of perceived stress, cortisol and depressive symptoms 
in adults diagnosed with PCS?  
2. Does cortisol mediate the relationship between perceived stress and depressive symptoms 
in adults diagnosed with PCS? 
Setting and Sample 
The study sample of N=17 adults diagnosed with PCS were recruited through general 
advertising efforts (See Appendix C). Recruitment sites included, Carilion Roanoke Memorial 
Hospital (CRMH) and Carilion affiliates, including the Carilion New River Valley (CNRV) 
Physical Medicine and Rehabilitation clinic and Jefferson College of Health Sciences (JCHS), 
Virginia Commonwealth University (VCU), and VCU Health System (VCUHS). Social media 
outlets including Facebook and Craigslist were added to maximize study recruitment. The 
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Carilion Clinic is a non-profit organization consisting of eight hospitals located in southwest 
Virginia (VA) and numerous care facilities within the service area, 17 of which are located in the 
Roanoke, VA area. CRMH is a 700+ bed hospital, and a certified level-one trauma center located 
in Roanoke, VA. The CRMH emergency department and the Carilion Clinic family medicine 
centers, together, see approximately 121,000 outpatients annually, an estimated 37,510 (31%) 
seen in Roanoke County alone (Roanoke Valley Community Health Needs Assessment, 
[RVCHNA] 2015); with at least 1,500 individuals having a diagnosis of PCS (Carilion, 2016). 
The CNRV Physical Medicine and Rehabilitation clinic, located in Radford, VA, is associated 
with CNRV Medical Center, a Carilion Clinic affiliate. The CNRV Medical Center serves more 
than 49,000 patients annually (New River Valley Community Health Needs Assessment, 
[NRVCHNA] 2016). Participants were also recruited through the distribution of recruitment 
brochures and flyers to Jefferson College resources (an affiliate of Carilion Clinic), by 
submission to the VCU TelegRAM for faculty/staff and students and VCUHS Employee Bulletin 
Board, by postings on Facebook and Craigslist in both the Roanoke and Richmond areas, and 
through snowball sampling from participants and individuals who had seen the advertisement 
and referred the study to family and friends. VCU is an urban university offering over 200 
programs of study at the undergraduate and graduate level (Virginia Commonwealth University, 
2017a). In the 2017-18 academic year, enrollment for both the main and health sciences campus 
was approximately 31,000 students (Virginia Commonwealth University, 2017b). The VCU 
Health System employs more than 12,000 individuals in the Richmond and the surrounding area 
(Virginia Commonwealth University Health System, 2017).  
To facilitate tracking recruitment strategies, when potential study participants were 
contacted by the study investigator for further information, they were asked how they heard 
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about the study. This question was included in the standardized telephone interview script 
developed to answer initial contact questions (See Appendix D). It was anticipated that such data 
would be helpful in identifying successful recruitment options for future studies in this 
population. 
Prior to participant recruitment and enrollment, the investigator received approval from 
the Institutional Review Board (IRB) of VCU. Inclusion criteria were (a) ages 21 and older; (b) 
diagnosis of PCS based on the 10th edition of the ICD-10 (WHO, 2015) and documented by the 
patient’s healthcare provider; (c) ability to communicate in English; and (d) an ability to 
understand and sign the consent form and complete the pencil and paper measures. Exclusion 
criteria were (a) an inability to follow study protocol, e.g. self-collect saliva specimen and/or 
participate in a study visit; (b) pregnancy or possibility of being pregnant and (c) a history of 
severe mental illness (e.g., schizophrenia, psychosis, bipolar).  
 The sample size required for successful completion of the study was N=30 adult 
individuals (men or women) diagnosed with PCS. The sample size required for this study was 
calculated using Cohen's (1988) guidelines for small, medium and large effect sizes. Using a 
large effect size (0.50) for the test of the null hypothesis H0: r = 0 versus the two-sided 
alternative HA: r <> 0 where r is the Pearson correlation coefficient with a significance level of  
p =0.05 and a desired power of 80%, it was determined that a sample size of N=26 was needed 
for this study. To account for the potential of a 20% drop-out rate, we planned to recruit N=30 
subjects diagnosed with PCS for the study.  
Procedures 
Screening Procedure (Appendix D)  
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Volunteers who were interested and self-selected to participate in the study were screened 
by the student investigator by telephone (if contacted by telephone) or in person (if contacted in 
person) in a private place convenient to the potential participant. The study, including risks and 
benefits, was explained in detail and all questions raised by the potential study participant were 
answered. If after the telephone screening procedure, the individual met inclusion criteria and 
agreed to participate, an appointment was made to meet at a place and time convenient to the 
participant that also afforded participant confidentiality. At that time, the study was explained 
once again, any participant questions answered, written informed consent (See Appendix E). 
obtained and the data collection protocol initiated. Upon completion of signed informed consent, 
the participant was asked to provide proof of diagnosis of PCS in the form of a medical record or 
signed note from the healthcare provider. If unable to provide proof of diagnosis, the participant 
was asked to complete and sign a HIPAA authorization release form (Appendix E) to enable 
contacting the healthcare provider for proof of diagnosis. If the participant was screened in 
person and was interested in participating, the study was explained once again, any participant 
questions answered, and if the participant was willing, written informed consent was obtained. 
After obtaining written informed consent, the data collection protocol was initiated. After 
obtaining written informed consent, the participant was asked to provide confirmation of PCS 
diagnosis. If the participant was unable to provide proof of diagnosis with either a note from 
their healthcare provider or a print out of the diagnosis from medical records, the participant was 
asked to complete and sign a HIPAA authorization release form to enable contacting the 
healthcare provider for proof of diagnosis. Data was de-identified with the assignment of a 
subject identification number, in consecutive order starting with 1001, at the time of consent. 
Details of the informed consent including date and time were recorded in study records and a 
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copy of the informed consent document were kept in a secure locked location for IRB purposes. 
A copy of the informed consent document was also provided to the participant. 
Following screening and informed consent, the data collection protocol was explained 
with study participants repeating back to the investigator the process and having time to ask 
questions for any points of needed clarification. A salivary cortisol collection system was 
provided to the participant with both verbal and written directions regarding how and when to 
collect the sample, and how to store the sample until pick up by the investigator. Full informed 
consent and collection of non-biological data was anticipated to take approximately 60 minutes. 
Measures (Appendix F) 
Non-biologic Measures. 
Demographic and Health History Questionnaire. 
Following informed consent, a self-report demographic and health history questionnaire 
was used to obtain information regarding age, race/ethnicity, marital status, date of original 
injury leading to diagnosis, date of PCS diagnosis, socioeconomic status, psychiatric history, 
medical history, and medication history. 
The Rivermead Post Concussive Symptom Questionnaire (RPQ).  
The Rivermead Post concussive Symptom Questionnaire (RPQ) (King, Crawford, 
Wenden, Moss, & Wade, 1995) is designed to measure postconcussive symptoms and symptom 
severity and was included as a method of phenotyping the study population. To be diagnosed 
with PCS, an individual must present with three or more symptoms of this syndrome (WHO, 
2015). This self-report measure is recommended for use in the mTBI and moderate TBI 
population by the National Institute of Neurological Disorders and Stroke (NINDS) (Wilde et al., 
2010). The RPQ is a 16-item survey measured on a 5-point Likert scale where participants 
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indicate and rate the experience of various PCS symptoms relative to their experience of the 
symptom prior to injury. Examples of symptoms that subjects are asked to rate include 
“headache”, “fatigue” and “restlessness”. The presence of symptoms are ranked from 0= “not 
experienced at all” to 4= “a severe problem” in the past 24 hours (King et al., 1995). The 
measure was scored with a total summed score and with the recommended method of scoring in 
two parts. The first part (RPQ-3) consists of scoring the first three items, which relate to early 
presenting symptoms of PCS (headache, dizziness and nausea and or vomiting). Scores range 
from 0-12 with higher scores indicating greater report of symptom severity and the need for 
closer symptom monitoring and assessment. The second part (RPQ-13) consists of scoring the 
remaining 13-items with scores ranging from 0-52; higher scores indicate greater report of 
symptoms and symptom severity (Eyres, Carey, Gilworth, Neumann, & Tennant, 2005). 
Although there is no reported statistical validity for this measure, in a sample of n=369 
individuals with a diagnosis of TBI, test-retest reliability coefficients for the RPQ-3 and RPQ-13 
was reported at 0.72 and 0.89 respectively (Eyres, Carey, Gilworth, Neumann, & Tennant, 
2005). When testing reliability with a total summed score, Eyres et al. (2005) reported poor item 
fit (µ - 0.416, SD 1.989) thus supporting findings obtained from the literature to score the 
measure in two parts as RPQ-3 and RPQ-13 (Lannsjö, Borg, Björklund, af Geijerstam, & 
Lundgren-Nilsson, 2011; Potter, Leigh, Wade, & Fleminger, 2006).  
Perceived Stress Scale (PSS).  
 The 10-item Perceived Stress Scale (PSS; Cohen et al., 1983) was used to measure 
perceived stress. The PSS measures the level to which situations are appraised as stressful 
(Cohen et al., 1983). The PSS is a valid and reliable measure in the TBI population (Bay & 
Donders, 2008; Bay et al., 2002; Bay et al., 2005; Bellon et al., 2015; Strom & Kosciulek, 2007). 
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It was anticipated that the PSS would take no more than 5 to 10 minutes to complete, thus 
addressing patient burden concerns (Cohen & Williamson, 1988). The 10-item PSS contains 
items that are measured on a 5-point Likert scale: 0 = “never”; 1= “almost never”; 2= 
“sometimes”; 3= “fairly often”; and 4 = “very often” over the past month. Some examples of 
items include “In the last month, how often have you been upset because of something that 
happened unexpectedly?” and “In the last month, how often have you felt that you were 
effectively coping with important changes that were occurring in your life?” The range of score 
is 0-40 with higher scores indicating higher report of perceived stress (Cohen et al., 1983). 
Cronbach’s alpha co-efficient for the scale has been reported as 0.87 when used in the mTBI and 
moderate TBI population, indicating high internal reliability (Bay et al., 2009).  
The Center for Epidemiologic Studies Depressive Scale (CES-D). 
The Center for Epidemiologic Studies Depressive Scale (CES-D; Radloff, 1977) was 
used to measure depressive symptoms. This self-report measure was designed for use in the 
general population to indicate depressive symptoms and is frequently used as a measure of 
depressive symptoms in both healthy and non-healthy populations (Radloff, 1977). The CES-D 
is a 20-item survey measured on a 4-point Likert scale where participants rate how they felt or 
behaved during the last week as “rarely”, “some”, “occasional”, or “most”; with four of the 20 
items scored negatively. Some examples of statements include “I was bothered by things that 
don’t usually bother me” and “I felt like people disliked me”. The range of score is 0-60 with a 
score of 16-20 indicating mild depression, 21-26 indicating moderate depression and a score 
greater than 27 indicating severe depression. The CES-D has been used as a measure of 
depression in the mTBI and moderate TBI populations (Bay et al., 2002; Bellon et al., 2015). 
Although not developed specifically for the neurologic population, the CES-D is recommended 
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for supplemental use in the TBI population as a measure of depression (NINDS, 2016). 
Cronbach’s alpha co-efficient for the scale has been reported as 0.92 when used in the mTBI and 
moderate TBI population indicating high internal reliability (Bay, Kalpakjian & Giordani, 2012). 
It was anticipated that this measure would take no more than 5 to minutes to complete (Spinal 
Cord Research Evidence, 2010). 
The Patient Reported Outcomes Measurement Information System (PROMIS) 
Emotional Distress Depression Scale- short form (PROMIS ED-Depression-SF). 
The CES-D was the primary measure of depressive symptoms in this study as this 
measure is frequently used as a valid and reliable measure of depressive symptoms (Radloff, 
1977). The PROMIS Emotional Distress (ED)-Depression-Short Form (SF) for adult individuals 
was included as a second measure of depression in the study. This self-report measure is 
designed to measure depressive symptoms listed in the DSM-V (American Psychological 
Association [APA], 2013). These symptoms include feelings such as sadness, loneliness and 
worthlessness.  The PROMIS-ED-Depression-SF was developed for use in general and chronic 
disease populations (PROMIS, 2015). Although not developed specifically for the neurologic 
population, the PROMIS-ED-Depression-SF has been recommended for use in the TBI 
population as part of the NIH CDE initiative to promote consistency among brain injury research 
findings (NINDS, 2016). The PROMIS ED- Depression Scale-SF is an 8-item survey measured 
on a 5-point Likert scale where participants rate how they felt during the last seven days as: 1= 
“never”; 2= “rarely”; 3=“sometimes”; 4= “often” or 5=“always”. Some examples of items 
include “I felt worthless” and “I felt helpless”. Scores range from 8-40. Scores are summed then 
converted to a T-score. T-scores range from 37.1 to 81.1 with higher scores indicating higher 
report of depressive symptoms. A T-score of <55 indicates no to slight depression, a score of 55 
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to 59.9 indicates mild depression, a score of 60.0 to 69.9 indicates moderate depression and a 
score >70 indicates severe depression (APA, 2013). Cronbach’s alpha co-efficient for the scale 
has been reported as 0.96 when used in mild, moderate and severe TBI populations indicating 
high reliability (Tulsky et al., 2016). As with the PSS and CES-D, we anticipated this measure 
could be completed within 5 to 10 minutes, thus minimizing patient burden. 
Biologic measure. 
Salivary Cortisol. 
Salivary cortisol was collected from study participants using the SalivaBio Oral Swab 
(SOS) Saliva Collection System from Salimetrics (2015). The amount of saliva collected using 
the SOS saliva collection system is 75 µL. Intra-assay precision for this collection system is 
reported to be between 4-7%, with an inter-assay precision of 3-11% and a serum cortisol 
correlation of 0.91 (Salimetrics, 2016). Normal awakening cortisol levels in adults range from 
0.094 to 1.551 µg/dL (Salimetrics, 2016). Although no studies have been identified exploring 
cortisol in the PCS population, Bay et al. (2005) explored correlations between perceived stress, 
salivary cortisol, and depression in N=75 men and women after mTBI and moderate TBI. The 
authors were not able to report statistically significant study findings related to salivary cortisol; 
however, they did report that that individuals with mTBI had significantly greater 8:00 a.m. 
(awakening) cortisol levels (t= 2.66, df 48, p=0.011) as compared to those with moderate TBI. It 
has been determined that salivary cortisol collection has advantages when compared to serum 
collection. Serum collection for cortisol requires the invasive procedure of venipuncture which 
may confound results due to activation of the stress response, making the salivary method 
preferred not only due to ease and convenience of data collection and decreased patient burden, 
but also to limit a potential confounding effect (Kirschbaum & Hellhammer, 1989). 
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Data collection protocol 
The student investigator obtained informed consent. Afterward, the investigator provided 
the non-biological self-report measures to the study participant and described the pencil and 
paper process. The order of completion was demographic form, RPQ, PSS, CES-D and PROMIS 
ED-Depression-SF. All measures, including the demographic form, were completed by the 
participant and collected by the investigator at this time. The student investigator then provided 
the participant with the salivary cortisol collection kit containing an oral swab and labeled 
collection tube. A biohazard bag was provided to place the collected sample prior to freezing. 
The student investigator explained and provided written directions on how to collect and store 
the salivary cortisol sample.  
Salivary Cortisol Sample Collection. 
Participants were asked to collect the salivary cortisol sample within seven days of 
having signed the consent form and completing all non-biological data collection measures.  
Participants were instructed to (a) write the date and time on the label or the biohazard bag 
provided to them along with the salivary collection kit (tube); (b) collect salivary cortisol sample 
in tube provided (as demonstrated to them by the investigator at the time of study enrollment); 
(c) place the salivary cortisol sample tube into the biohazard bag; (d) place the sealed biohazard 
bag with salivary cortisol sample inside into their home freezer; (e) notify the study investigator, 
by text, email, or phone, that they had collected the sample and arrange an agreed-upon time for 
the student investigator to personally collect the salivary cortisol sample. To enhance needed 
study protocol compliance, a method of reminding the participant to collect the sample within 30 
minutes of awakening was negotiated with each study participant by the study investigator at the 
time of study enrollment. This was done with a reminder text or e-mail at a predetermined time. 
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Because stressful events the evening before collection could lead to an elevated cortisol, the 
participant was asked to collect the sample after what they would consider to be a ‘routine’ night. 
At the time of pick up, the investigator received the sample and maintained the sample in a 
frozen state until transportation to VCU School of Nursing (VCU SON) where all frozen 
specimens were stored at or below -80C until thawed for batch processing and analysis.  At study 
completion, each study participant received a $10 gift card.   
Risk Reduction. 
This study involved minimal risk due to the exploratory nature of the research plan. 
Participants were notified that they may refuse any portion of the data collection. No participant 
appeared to experience emotional discomfort in completing the measures. If a participant were to 
have experienced greater than expected emotional distress, the study visit would have been 
terminated and the participant withdrawn from the study. The student investigator would have 
remained with the participant until a support person arrived or until the emotional distress 
resolved. The participant would have been encouraged to speak with their healthcare provider 
about their distress. To further minimize risk, participants reporting CES-D scores greater than 
16, indicating the potential for a diagnosis of depression (Radloff, 1977), were informed at the 
time of data collection or by the method of preferred communication on the day of data 
collection and referred to their healthcare provider for further assessment.  
Data Management and Analysis 
Data Management 
All data was maintained electronically on a password-protected computer with secure 
network server access at VCU School of Nursing. Hard copy material such as the demographic 
form and consents containing identifiable information were maintained by the study investigator 
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in a locked cabinet within a locked room in the investigators Roanoke office until the study was 
completed. Upon study completion, the measures were transported to the principle investigators 
office at VCU SON to be maintained under the same conditions. Salivary cortisol samples were 
frozen immediately following collection and remained frozen until thawed for batch processing 
and analysis. Once received by the laboratory, samples were stored in a freezer at or below -80C 
until processing. All samples from a single participant were assayed together to reduce interassay 
variability. Assays were performed per manufacturer's guidelines. All study material will remain 
stored and locked in secure location in the office of research at VCU SON and then destroyed 
within seven years after study completion per VCU policy.  
Data Analysis 
The student investigator entered all data into the JMP Pro-14 statistical package for 
analysis. Statistical significance was set with an alpha of 0.05. 
Step 1: Descriptive 
Descriptive statistics were described with medians and ranges for variables such as the 
demographics of age, time since original injury leading to diagnosis of PCS, time since PCS 
diagnosis and RPQ scores. Race/ethnicity, marital status, sex, and socioeconomic status were 
described with numbers and frequencies. A comparison was made between subjects with 
confirmed diagnosis (n=10) and those without confirmation (n=7). 
Step 2: Correlation analysis  
For specific aim 1: Examine the relationships among perceived stress, symptoms of 
depression and cortisol levels in persons diagnosed with PCS; Spearman’s Rank Order 
Correlation Coefficient was used to examine relationships between stress and cortisol; stress and 
depression; and cortisol and depression.  
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Step 3: Mediation analysis 
For specific aim 2: Examine the mediating effect of cortisol between perceived stress and 
levels of depression in persons diagnosed with PCS; Spearman’s Rank Order Correlation 
Coefficient was used to determine relationships between variables. We had planned to use 
mediation analysis to determine the mediating effect, if any, of cortisol. Mediation analysis is a 
four-step process described by Baron and Kenny (1986). The four steps are as follows: (1) 
perform a simple regression analysis between perceived stress and depression; (2) perform a 
simple regression analysis between perceived stress and cortisol; (3) perform a simple regression 
analysis between cortisol and depression. If relationships exist in all three steps, then (4) perform 
a multiple regression analysis of perceived stress, cortisol and depression. If any one of the first 
three steps is found to have no relationship, mediation is not likely and step four is not 
performed.  
Step 4: Cronbach’s alpha 
The RPQ, PSS, CES-D and PROMIS ED-Depression short form were statistically 
analyzed for validity and reliability in this study population. We have reported the findings with 
Cronbach's alpha thus contributing to the reliability of these measures for use in the adult PCS 
population. Additionally, a correlation analysis was performed between the CES-D and PROMIS 
ED-Depression short form.  
Summary 
 This was a feasibility study using a descriptive, cross-sectional design to examine 
relationships among perceived stress, cortisol levels and depressive symptoms in adult persons 
diagnosed with PCS; with the hopes of exploring a mediating effect of cortisol between 
perceived stress and levels of depression in this population. Symptom characteristics were 
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identified and described. Study measures, such as the PSS, CES-D and PROMIS ED-Depression 
SF were assessed for reliability in the PCS population. Study findings will be used to power a 
larger exploratory study in the PCS population and to inform a future PNI-based intervention 
study. In chapter four, we discuss the study findings in relation to the study hypothesis.  
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Chapter IV 
Results 
 The purpose of this descriptive cross-sectional study was to explore and describe 
relationships among levels of perceived stress, levels of cortisol as a biological indicator of HPA 
axis dysregulation, and levels of depression, in persons diagnosed with PCS. The findings related 
to the following research questions are reported in this chapter.  
1. Is there a correlation among levels of perceived stress, cortisol, and symptoms of 
depression in adults diagnosed with PCS?  
2. Does cortisol mediate the relationship between perceived stress and symptoms of 
depression in adults diagnosed with PCS? 
Recruitment 
Following VCU IRB approval, participants were recruited from May 2017 through June 
2018. Self-selection sampling was the primary strategy in participant recruitment for this study. 
A total of 49 persons from the New River and Roanoke Valleys, and the Richmond area, 
contacted the student investigator and expressed interested in the study (see Figure 1). Of the 49 
interested persons, 36 persons were screened for eligibility. Inability to retrieve telephone 
numbers for the purpose of eligibility screening was the primary reason for not screening 
potentially interested persons; meaning the individual had contacted the student investigator by 
email to express interest in the study, however, did not return the student investigators email 
requests for telephone contact information to discuss the study and potentially screen for 
eligibility (see Table 1). In an attempt to identify successful recruitment options for future 
studies in the PCS patient population, those persons who were screened for eligibility were asked 
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how they found out about the study. The majority of respondents became aware of the study 
from the Richmond Craigslist advertisement (see Table 2).   
Figure 1. Participant Tracking Report from Interest through Completion of Data Collection. 
______________________________________________________________________________  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________ 
Figure 1. Participant tracking demonstrating flow from time of response to general 
advertisement, i.e. interest, through screening, eligibility, enrollment and study completion. 
 
 
Interested: N= 49 
Screened: n=36 Not Screened: n=13 
 
Enrolled: n=17 
Completed Study Visit one: n=17 
Completed Study Visit two: n=15 
Eligible: n=25 Ineligible: n=11 
Eligible, not 
Interested: n=8 
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Table 1  Rationale for not Screening Interested Persons for Eligibility 
______________________________________________________________________________ 
Rationale                                                                                    Number of Persons 
Not responding to return call/email           n=7 
Interested in study for a friend or family member                                   n=5 
Inpatient at a rehabilitation facility                                                          n=1 
______________________________________________________________________________ 
Total                                                                                                        N=13 
Table 2  Study Advertisement Tracking Information Collected from Interested Persons who were 
Screened for Eligibility 
________________________________________________________________________ 
Advertisement Source                Number 
Jefferson College of Health Sciences      n=3 
Carilion and Affiliates        n =7 
Craigslist Roanoke                    n =6 
Craigslist Richmond                   n =14 
VCU & VCUHS              n =3 
Third Party Sources      n =3 
______________________________________________________________________________ 
Total                                                                                                           N= 36 
Note. VCU= Virginia Commonwealth University; VCUHS= Virginia Commonwealth University 
Health System 
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Of the 36 persons who were screened, 25 were found to meet eligibility criteria. A lack of 
formal diagnosis due to not seeking care for head injury and/or persistent postconcussive 
symptoms was the primary reason for not meeting eligibility criteria (see Table 3). Of the 25 
individuals who were screened and found eligible to participate, N=17 (n=13 females; n=4 
males) agreed to participate in the study. There were eight individuals who met 
inclusion criteria but declined participation related to concerns of time commitment and/or lack 
of financial incentive.  
Table 3 
Persons Screened who did not Meet Eligibility Criteria 
______________________________________________________________________________ 
Reasons for Ineligibility                   Number of Persons 
Not formally diagnosed                                                                               n=9 
Major psychiatric history                                                                             n=1 
Younger than 21 years                                                                                 n=1 
______________________________________________________________________________ 
Total                                                                                                           N=11 
Of the 17 participants who enrolled in the study, 15 (n=11 females; n=4 males) 
completed all study instruments and salivary cortisol sample collection at both time points. 
Subjects were instructed verbally and in writing to collect the salivary cortisol sample 30 to 45 
minutes after awakening, after what participants considered a ‘normal’ evening, within seven 
days of the initial study visit and to record the date and time of collection. Salivary cortisol 
samples (N=15) were reported by the participants as being collected between 0604 and 1032 in 
the morning, with collection occurring within a range of 2 to 17 days (median 9 days) after the 
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initial study visit. Due to difficulties in obtaining proof of diagnosis with either a note from their 
healthcare provider or a print out of the diagnosis from medical records, n=7 diagnoses were not 
confirmable by medical record. Barriers to confirmation included a lack of response to diagnosis 
confirmation requests from healthcare providers, inability of the healthcare provider to confirm 
or deny diagnosis of PCS, and the inability of the participant to find a medical record that they 
believed they had possession of. All 17 participants did self-report both date of head injury and 
date of PCS diagnosis. 
Demographic Characteristics 
Despite a persistent and multi-pronged recruitment strategy, a sample size was not 
achieved that would power this study and we cannot assume the sample variable means are 
normal; therefore, demographic data is described with medians and ranges. The significance 
level was set at p=0.05. Group (healthcare provider confirmed diagnosis and unconfirmed 
diagnosis) medians were compared with the non-parametric Wilcoxon Rank-Sum (Mann-
Whitney U) test for continuous variables and Pearson’s Chi Square for categorical data. The 
study sample consisted primarily of Caucasian women. The median age of the total study sample 
was 38 years with a range of 22 to 61 years. Participants reported having experienced an mTBI 
between 2 months to 109 months (9 years) with a median of 14 months from the date of the first 
study visit. The reported time between mTBI and diagnosis of PCS for this sample ranged from 0 
to 34 weeks (median of 3 months), and the time between diagnosis of PCS and the first study 
visit was reported between 1 week to 105 weeks (24 months) with a median of 15 months (see 
Table 4). The socioeconomic status of the sample varied, as did the relationship status. Notably, 
only one participant elected not to divulge their socioeconomic status and no participant reported 
being divorced or separated (see Table 5). More than half (n=9) of all participants reported being 
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diagnosed with depression and/or anxiety disorder and reported taking antidepressant or 
antianxiety medication. The median RPQ score was 46.  
Table 4 
Demographics: Continuous Variables and Group Comparison 
 
 
 
 
Variable 
 
 
Total Sample 
(N=17) 
Median (Range) 
 
Confirmed  
Diagnosis 
(n=10) 
Median (Range) 
 
Unconfirmed  
Diagnosis 
(n=7) 
Median (Range) 
 
p-value 
Age in years 38(22, 61) 46 (23, 61) 38 (22, 49) 0.2034 
Time Since Head  
Injury in Months 
13.8 (2.1, 108.6) 18.0 (3.5, 108.6) 12.7 (2.1, 72.0) 0.8073 
Time between Head  
Injury and PCS  
Diagnosis in Weeks 
2.7(0.0, 34.1) 5.0 (0.0, 34.1) 2.0 (0.0, 17.4) 0.4919 
Time between PCS  
Diagnosis and Study  
visit one in Months 
14.6(1.4, 104.7) 20.1 (3.5, 104.7) 11.1 (1.4, 72.0) 0.7327 
Rivermead 
Postconcussion 
Questionnaire (RPQ) 
46 (8, 57) 46 (8, 57) 36 (15, 55) 0.9610 
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Table 5 
 
Demographics: Categorical Variables and Group Comparison 
 
 
 
Variable 
Total 
Sample 
(N=17) 
Confirmed 
Diagnosis 
(n=10) 
Unconfirmed 
Diagnosis 
(n=7) 
 
 
Χ2 
 
 
p-value 
Sex  
     Male 
     Female 
 
4 (24%) 
13 (76%) 
 
2 (20%) 
8 (80%) 
 
2 (29%) 
5 (71%) 
0.17 0.6818 
Ethnicity  
     Hispanic 
     Non-Hispanic 
 
1 (6%) 
16 (94%) 
 
0 (0%) 
10 (100%) 
 
1 (17%) 
6 (83%) 
1.51 0.2179 
Race  
    Asian 
    Hispanic 
    Caucasian 
    African American 
 
1 (6%) 
1 (6%) 
14 (82%) 
1 (6%) 
 
0 (0%) 
0 (0%) 
10 (100%) 
0 (0%) 
 
1 (14%) 
1 (14%) 
4 (58%) 
1 (14%) 
5.20 0.1574 
Income   
     <14,000 
     14-24,999 
     25-34,999 
     35-49,000 
     50,000 or > 
     No response 
 
2 (12%) 
1 (6%) 
4 (24%) 
1 (6%) 
8 (47%) 
1 (6%) 
 
1 (10%) 
1 (10%) 
2 (20%) 
0 (0%) 
6 (60%) 
0 (0%) 
 
1 (14%) 
0 (0%) 
2 (29%) 
1 (14%) 
2 (29%) 
1 (14%) 
3.20 0.5249 
Relationship Status 
    Living with partner 
    Married 
    Single/never married   
 
4 (24%) 
8 (47%) 
5 (29) 
 
4 (40%) 
4 (40%) 
2 (20%) 
 
0 (0%) 
4 (57%) 
3 (43%) 
3.78 0.1504 
 
When comparing groups between those with confirmation of diagnosis and those without 
for both continuous and categorical variables, no significant differences were found. Median 
scores for those with a confirmed diagnosis were found to be slightly higher in the variables of 
age (+ 8.5 years), time since mTBI (+ 5.25 months), time between mTBI and diagnosis of PCS 
(+ 3 weeks), and time between diagnosis of PCS and the first study visit (+ 9 months). Those 
participants with a confirmed diagnosis reported a median RPQ score 10 points higher than those 
without a confirmed diagnosis. Of those with confirmed diagnosis, more than half ranked the 
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symptoms of ‘fatigue’ as being a severe problem since their head injury (M=4). Symptoms 
reported as causing a moderate problem (M=3) include ‘dizziness’, ‘irritability’, ‘frustration’, 
‘forgetfulness’, ‘poor concentration’ and ‘taking longer to think’. The symptom of depressed 
mood was reported as being a mild problem (M=2). These findings share similarities with 
findings from the unconfirmed diagnosis group, with ‘fatigue’, ‘forgetfulness’, and ‘taking 
longer to think’ reported as a severe problem (M=4), and symptoms reported as a moderate 
problem (M=3) including ‘headache’, ‘sleep disturbance’, ‘irritability’, ‘feeling depressed’, 
‘frustration’, and ‘poor concentration’.  
Outcome Variables 
Descriptive statistics for the variables of perceived stress, salivary cortisol and depression 
were described with medians and ranges as we cannot assume that this data is normally 
distributed due to the small sample size. Group medians of the study measures were compared 
with the non-parametric Wilcoxon Ranked-Sum (Mann-Whitney U) test. Although the groups, 
those with confirmed diagnosis and those without, are both reported; only the analysis for those 
with confirmed diagnosis was used for hypothesis testing. For those with confirmed diagnosis, 
the median score for the PSS, was 25 (range of 16 to 31). The median score for the CES-D, was 
29 (range of 10 to 47) and the median measurement of salivary cortisol was 7 nM/L (range of 4 
to 21 nM/L) for those with confirmed diagnosis (see Figure 2).  
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Figure 2. Box Plot of Salivary Cortisol Results for groups 
 
Figure 2. A Quantile Box plot of cortisol levels for those with confirmed diagnosis and those 
without a confirmed diagnosis. The median level for those with confirmed diagnosis was 6.9 
nM/L (IQR 4.6 to 11 nM/L). The mean level was 8.7 nM/L (SD 5.4). The median level for those 
without confirmed diagnosis was 11.4 nM/L (IQR 6.2 to 23.4 nM/L). Note nM/L=nanomoles per 
liter. 
When comparing descriptive statistics for outcome variables between those with and 
without diagnosis, we find there are no significant differences between groups (see Table 6). The 
medians were slightly lower for those with confirmed diagnosis for the biological variable of 
cortisol and slightly higher for the variables of perceived stress and CES-D as the primary 
measure of depression than those without confirmed diagnosis 
54 
 
 
Table 6 
 
Descriptive Statistics for Study Measures with Group Comparison 
 
 
 
 
 
Variable 
 
Total 
Sample 
(N=17) 
Median 
(Range) 
 
Confirmed 
Diagnosis 
(n=10) 
Median 
(Range) 
 
Unconfirmed 
Diagnosis 
(n=7) 
Median 
(Range) 
 
p-value 
Perceived Stress 
Scale (PSS) 
23 (6, 31) 25 (6,31) 
 
22 (16, 27) 0.5901 
Center for 
Epidemiologic 
Studies Depression 
Scale 
(CES-D) 
25 (10, 47) 29 (10, 47) 25 (12, 38) 0.7325 
PROMIS Emotional 
Distress-Depression 
Short Form 
(PROMIS ED-SF) 
19 (8, 34) 23 (12, 34) 19 (8, 25) 
 
0.3765 
Salivary Cortisol in 
nanomole per liter 
(nM/L) 
8 (4, 35) 7 (4, 21) 11 (6, 35) 0.2979 
 
Hypothesis 1: There is a correlation among levels of perceived stress, cortisol, and depression in 
persons diagnosed with PCS. Spearman’s Rank Order Correlation Coefficient was used to 
analyze relationships of the variables of perceived stress and salivary cortisol, salivary cortisol 
and depression, and perceived stress and depression among the study sample with a confirmed 
diagnosis (see Table 7). No significant relationships were found between PSS scores and cortisol 
levels (Spearman rho= -0.09; p= 0.8016) or between cortisol levels and CES-D scores (Spearman 
rho= -0.09; p= 0.8022), however there was a statistically significant relationship noted between 
PSS scores and CES-D scores (Spearman rho=0.91; p= 0.0002).  Because no significant 
relationships were found in two of the three pairs of variables, we fail to reject the null 
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hypothesis meaning there is not enough evidence to demonstrate whether the variables do or do 
not correlate. 
Table 7 
Results of Correlational Analysis of PSS, Cortisol and CES-D  for Sample with Confirmed 
Diagnosis 
 
 PSS 
Total Score 
p- value 
CES-D 
Total Score 
p- value 
Cortisol 
(nM) 
p- value 
 
PSS Total Score 
 
 
 
0.0002 * 
 
 
 
0.8016 
 
 
CES-D Total Score 
   
0.8022 
 
Note. PSS=Perceived Stress Scale; CES-D= Center for Epidemiological Studies Depression 
Scale; nM=Nanomole; *= Statistical Significance. 
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Figure 3. Scatterplot Demonstrating Relationships between Stress, Depression and Cortisol 
Scores in the Sample with Confirmed Diagnosis  
 
Figure 3. A visual representation of the relationships between perceived stress and depression as 
measured by the CES-D in the sample with confirmed diagnosis of PCS. PSS= Perceived Stress 
Scale; CES-D= Center for Epidemiological Studies Depression scale; nM=nanomoles; 
PCS=Postconcussion Syndrome.  
No significant correlations were found between PSS scores and cortisol levels (Spearman 
rho= -0.11; p = 0.6887), or between cortisol levels and CES-D scores (Spearman rho= -0.10; p= 
0.6989) in the total sample, however there was a statistically significant positive relationship 
identified between PSS scores and CES-D scores (Spearman rho= 87; p < 0.0001); meaning that 
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higher reported levels of perceived stress appeared to correlate to higher reported levels of 
depression (see Table 8). 
Table 8 
Correlational Probability of PSS, Cortisol and CES-D for Total Sample 
 PSS 
Total Score 
p- value 
CES-D 
Total Score 
p- value 
Cortisol 
(nM) 
p- value 
 
PSS Total Score 
 
 
 
0.0001* 
 
0.6887 
 
CES-D Total Score 
  
 
 
0.6989 
 
Note. PSS= perceived stress scale; CES-D= Center for Epidemiological Studies Depression 
scale; *=statistically significant. 
For Hypothesis 2: Cortisol mediates the relationship between levels of perceived stress 
and depression in persons diagnosed with PCS. We did not perform a multiple regression of 
variables as significant correlation among all variables was required for the analysis of cortisol as 
a mediator. We did not find a significant correlation between perceived stress and cortisol, and 
cortisol and depression, meaning that cortisol was unlikely to mediate these relationships. Thus, 
we were unable to reject the null hypothesis. 
Reliability of Study Measures 
Non-biologic Measures 
Study measures were assessed for item reliability. Multivariate analysis was used to 
identify the Cronbach’s alpha co-efficient for each measure. In this study, the RPQ was used for 
descriptive purposes. The Cronbach alpha co-efficient for the instrument in this sample was 0.96 
indicating high internal reliability. When exploring internal reliability of the RPQ in two parts, 
the RPQ-3 and RPQ-13, the instrument remains reliable with a Cronbach alpha co-efficient of 
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0.70 and 0.95 respectively. The Cronbach’s alpha co-efficient for the PSS in this sample was 
0.86, indicating high internal reliability. The Cronbach’s alpha co-efficient for CES-D was 0.92 
for this sample, meaning the measure demonstrated high internal reliability. The PROMIS-ED-
Depression SF was used as a secondary measure of depression for the purpose of comparing 
reliability with the CES-D in order to contribute to the National Institutes of Health (NIH) 
Common Data Element (CDE) initiative. The Cronbach’s alpha co-efficient for the PROMIS-
ED-Depression SF in this sample was 0.96 indicating high internal reliability. When comparing 
total scores between the CES-D and the PROMIS-ED-Depression SF, we found a significant 
correlation in scores (p<0.0001). When comparing reliability of the measures by group, those 
with a confirmed diagnosis and those without a confirmed diagnosis, we found similar results. 
Thus, study instruments demonstrated high internal reliability of all measures with the exception 
of the RPQ-3 and the PSS scores in the unconfirmed diagnosis group (see Table 9).  
Table 9 
Study Measure Item Reliability  
 Total Confirmed 
Diagnosis 
Unconfirmed 
Diagnosis 
Study Measure Cronbach’s α Cronbach’s α Cronbach’s α 
 
RPQ Total Score 
     RPQ-3 
     RPQ-13 
 
0.96 
0.70 
0.95 
 
0.96 
0.77 
0.96 
 
0.95 
0.45 
0.95 
 
PSS 
 
0.86 
 
0.91 
 
0.61 
 
CES-D 
 
0.92 
 
0.94 
 
0.82 
 
PROMIS ED-SF 
 
0.96 
 
0.96 
 
0.92 
 
Note. RPQ=Rivermead Postconcussion Questionnaire; PSS= Perceived Stress Scale;  
CES-D= Center for Epidemiological Studies Depression scale. 
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Biological Measure 
Salivary cortisol was collected from participants using the SalivaBio Oral Swab (SOS) 
Saliva Collection System from Salimetrics (2015). Intra-assay precision for this collection 
system is reported to be between 4-7%, with an inter-assay precision of 3-11% (Salimetrics, 
2016). The amount of saliva collected using the SOS saliva collection system was 75μL. The 
samples were analyzed by the Biobehavioral Research Laboratory at the Virginia 
Commonwealth University (VCU) School of Nursing (SON) using Enzyme Linked 
Immunosorbant Assay (ELISA) methodology. A total of N=15 frozen samples were delivered to 
the lab where they remained frozen until batch analysis. When data collection was completed, all 
samples were thawed. Once thawed, saliva samples were centrifuged at 1000 x g to remove any 
particulates, and 25 μL pipetted into four separate wells to obtain quadruplicate data for each 
sample. Optic density (OD) and percent bound (B/BO) were calculated for each sample, and the 
mean of four values were obtained for each participant. In tandem, duplicate values were 
obtained for high and low controls and cortisol standards. A four-parameter curve fit was 
performed with a total sum of square (SST) of 0.12 and an R² of 0.99, indicating excellent fit. 
Concentrations for each sample in nM/L were calculated using the standard curve. As expected, 
the mean value for the low control was 4.23 nM/L and the mean value for the high control was 
30.09 nM/L. The mean cortisol level for the total sample was 10.5 nM/L. 
Summary 
The purpose of this study was to explore and describe relationships among levels of 
perceived stress, cortisol as a biological indicator of stress, and levels of depression in persons 
diagnosed with PCS. A total n=10 subjects were confirmed to have a PCS diagnosis and were 
included in hypothesis testing. No significant differences were found between those subjects 
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with a confirmed diagnosis and those without diagnosis, demographically or in measurement of 
the outcome variables. A significant correlation was found between perceived stress and 
depression only. Questions remain as to a potential mediating effect of cortisol on these variables 
as study findings have led us to fail to reject the study H0. Chapter Five, includes a discussion of 
the study findings and the implications of these findings for nursing practice and future study.  
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Chapter V 
Discussion and Implications 
The study was a cross-sectional pilot study to (a) examine the potential relationships 
among the variables of perceived stress, salivary cortisol and depression in adults diagnosed with 
postconcussion syndrome (PCS) and (b) examine cortisol as a potential mediator between the 
variables of perceived stress and depression. In this chapter, the study results are discussed in 
relation to the hypotheses: (1) “There is a correlation between levels of perceived stress, levels of 
cortisol, and depression in persons diagnosed with PCS”, and (2) “Cortisol provides a mediating 
effect between levels of perceived stress and depression in persons diagnosed with PCS”. Study 
results demonstrated a statistically significant correlation between perceived stress and 
depressive symptoms (Spearman rho=0.87; p <0.0001); however, there were no reported 
correlations between the variables of perceived stress and cortisol (Spearman rho= -0.11; p 
=0.6887); nor between depression and cortisol as measured by CES-D (Spearman rho= -0.10; 
p=0.6989) or the PROMIS ED-Depression SF (Spearman rho= -0.40; p=0.1327). These findings 
suggest that cortisol is not likely to be a mediator between the specific variables of perceived 
stress and depression. We suggest that this may be due to the complexity of symptomatology 
associated with PCS or to a small sample size related to unexpected recruitment challenges, or 
perhaps, to both issues. Due to difficulty obtaining proof of diagnosis for all participants prior to 
data analysis, we discuss the study results by groups. Of the total sample (N=17), we have placed 
subjects in groups by diagnosis; those with confirmed diagnosis (n=10) and those with 
unconfirmed diagnosis (n=7). In addition to discussing study results, in this chapter we compare 
the study findings to previous studies in mild traumatic brain injury (mTBI) and moderate TBI 
populations. We discuss strengths and barriers to the recruitment strategy and enrollment, other 
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study limitations and reports of unexpected findings related to fatigue. Finally, we present 
implications for nursing practice and directions for future research. 
Discussion of Study Results 
Perceived Stress and Depression  
In this study, there were statistically significant correlations between perceived stress as 
measured by the Perceived Stress Scale (PSS) and depression as measured by the Center for 
Epidemiological Studies Depression scale (CES-D) (Spearman rho= .87; p <0.0001) and 
perceived stress and depression as measured by the Patient Reported Outcomes Measurement 
Information System (PROMIS) Emotional Distress Depression Scale- short form (PROMIS ED-
Depression-SF) (Spearman rho=.82; p < 0.0001). Cronbach’s alpha for all measures were strong, 
i.e., PSS (0.86), CES-D (0.92) and PROMIS ED-Depression-SF (0.96). Because of the very 
small sample size, we also examined medians and interquartile ranges (IQR) in the total sample 
(N=17) and by groups (confirmed diagnosis n =10; unconfirmed diagnosis n=7). The median 
(interquartile range) PSS scores were 23 [18, 27] for the total sample (N=17); with a median 
(interquartile range) of 25 [14, 30] for those with confirmed diagnosis (n=10); and 22 [20, 25] for 
those with unconfirmed diagnosis (n=7). These results indicate the presence of moderate levels 
of perceived stress in the study sample, regardless of the status of their diagnosis, with both 
groups reporting the experience of similar levels of perceived stress. The median (interquartile 
range) CES-D scores were 25 [18, 28] for the total sample; 29 [15, 45] for those with confirmed 
diagnosis; and 25 [19, 35] for those with unconfirmed diagnosis (n=7). These results suggest a 
study sample experiencing moderate to severe depression, with those having a confirmed 
diagnosis (n=10) reporting more severe depressive symptomology. When describing reports of 
depressive symptoms collected by the PROMIS ED-Depression SF, findings also suggest the 
63 
 
 
presence of moderate to severe levels of depression. That is, median (interquartile range) 
depression scores were 58 [54, 66] for the total sample; 61 [51, 70] for those having a confirmed 
diagnosis; and 58 [56, 63] for those with unconfirmed diagnosis. When exploring the report of 
depression scores as collected by both the CES-D and PROMIS ED-Depression SF, the study 
sample having a confirmed diagnosis (n=10) of PCS were found to report greater depressive 
symptomatology as described by both measures. In reporting the medians and means of 
perceived stress as collected by the PSS, and depressive symptoms as collected by both the CES-
D and PROMIS-ED-Depression SF, we hope to add to our understanding of these variables in 
the PCS patient population.  
To our knowledge, there are no known studies describing the relationship between 
perceived stress and depression in persons diagnosed with PCS. Examining the literature, we 
found studies examining similar variables, predominantly in the mTBI and moderate TBI patient 
population. For example, among research studies reporting a relationship between perceived 
stress and depression in the TBI population; Bay, Hagerty, Williams, Kirsch and Gillespi (2002) 
used a cross-sectional design to explore a potential relationship among post-injury stress and 
depressive symptoms in persons diagnosed with mild to moderate brain injury (N=75; men n=39; 
women, n=36). They found a significant relationship between perceived stress and depressive 
symptoms (R²=.54; p=.00). In this study, the authors also reported means for variables of stress 
and depression; describing a mean stress score of 28 (SD 9.5) and a mean depression score of 20 
(SD 13.2) in their sample. Of this study sample, the authors reported 20% (n=15) were found to 
have depression scores indicative of the presence of severe depressive symptomology. In a 
secondary analysis of the data from Bay et al. (2002), Bay, Sikorskii, & Gao (2009) reported 
finding a positive relationship (β =0.51; p<0.01) between perceived stress and depression, with 
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higher reports of perceived stress correlating with higher reports of depressive symptoms. In a 
separate study, Bay and Donders (2008) used a cross-sectional design to describe the role of 
chronic stress in the development of depressive symptoms after a TBI in a sample of individuals 
diagnosed with mTBI or moderate TBI (N=84; men n=43; women n=41). Noting that all study 
participants had been diagnosed with TBI between one and 36 months from the date of data 
collection, the researchers reported that the presence of depressive symptoms after TBI could be 
explained by reported levels of perceived stress (R²=.55), adding to the evidence that perceived 
stress shares a significant positive relationship to depression in the TBI population. While the 
authors did not report median or mean stress score for the total sample (N=84), the median 
depressive score was reported as 32. In this study, Bay and Donders (2008) placed subjects in 
groups by presence or absence of depression as identified by depression scores that identified 
those at risk (n=49) and those not at risk (n=35) for depression (i.e., depressed or not depressed). 
The authors reported mean stress scores for both the depressed group (x̅ 27, SD 5.5) and not 
depressed group (x̅ 20, SD 4.3). The mean depression score for the depressed group was 40 (SD 
6.1) and the not depressed group was 21 (SD 4.4). These reported study results indicate that 
individuals in the depressed group reported higher levels of perceived stress than those in the not 
depressed group. Strom and Kosciulek (2007) used a cross-sectional research design to examine 
relationships between perceived stress and depression in individuals diagnosed with mTBI 
(N=94; men n=35; women n=58). The researchers reported a significant (β=0.67; p< 0.001) 
correlation between perceived stress and depression. The mean stress score in this sample was 
reported to be 29 (SD 9.3) with a mean depression score of 17 (SD 10.8). The findings described 
by Strom and Kosciulek (2007) indicate a study sample reporting the presence of high levels of 
stress and mild to moderate depression. In a randomized control trial comparing the effect of a 
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12-week walking intervention to a 12-week control nutrition education program, Bellon et al. 
(2015) compared levels of perceived stress and depressive symptoms in a sample (N=69; men 
n=41; women n=28) diagnosed with mild, moderate or severe TBI. The researchers did not 
report comparisons of perceived stress and depression scores; however, mean scores of both 
measures were reported at each time point of this interventional study. The mean stress scores at 
baseline were reported as 26 (SD 9.5) for the interventional walking group and 23 (SD 9.2) for a 
control nutrition education group, indicating the presence of moderate perceived stress in both 
groups. The mean depression scores were reported as 16 for both the walking group (SD 12.4) 
and the control nutrition education group (SD 12.1) at baseline, indicating the presence of mild 
depressive symptoms in both groups. At study completion (24 weeks), both the intervention 
walking and control nutrition education groups reported a mean stress score of 21 (SD 9.5 
walking group; SD 9.2 nutrition group) and a mean depression score of 13 (SD 10.5 walking 
group; SD 11.4 nutrition group), indicating a decrease in levels of reported perceived stress and 
absence of depression. These findings support the evidence of the presence of higher reported 
levels of perceived stress and depression in the TBI population. Additionally, the findings 
reported in this study demonstrate the potential clinical significance of interventions that address 
symptoms of perceived stress and depression in the TBI population, and potentially, in the PCS 
population. While collectively these studies support the presence of a relationship between 
perceived stress and depression in the mTBI, moderate TBI and severe TBI populations, to our 
knowledge, there are no known studies to support this relationship in the PCS population. 
Therefore, we suggest that current study findings support an association between perceived stress 
and depression in persons diagnosed with PCS and, in this light, study findings contribute to 
addressing a gap in the science of PCS research.   
66 
 
 
Cortisol as a mediator. 
 In this study, cortisol was hypothesized to mediate the relationship between perceived 
stress and depression. Analysis of study results did not evidence a significant correlation between 
perceived stress and cortisol (Spearman rho= -0.11;  p= 0.6887) nor between depression and 
cortisol as measured by either the CES-D (Spearman rho= -0.10; p= 0.6989) or the PROMIS ED-
Depression SF (Spearman rho= -0.40; p=0.1327). Because there were no statistically significant 
correlations between cortisol and either stress or depression, the study findings did not meet 
criteria for mediation analysis as described by Baron and Kenny (1986); meaning, cortisol was 
unlikely to mediate the relationships between stress and depression. We examined medians and 
means of the cortisol levels in the total sample (N=17) and in groups (confirmed diagnosis n =10; 
unconfirmed diagnosis n=7). We report median cortisol levels due to our small sample size with 
the understanding that the literature reports standardized values as mean values. Regardless of 
how reported, means or medians, we found cortisol levels in our study sample as being below the 
published standardized normal mean of 13.05 nM/L diurnal cortisol release patterns (Salimetrics, 
2016). In congruence with the current nursing literature that reports on salivary cortisol, we 
report our study findings on cortisol in nanomole per liter (nM/L). The median level of salivary 
cortisol in the study sample was 7.5 nM/L (x̅ 10.5; SD 8.1). When describing findings by group, 
the cortisol level for those with confirmed diagnosis was 6.9 nM/L (x̅ 8.7; SD 5.4) and for those 
with unconfirmed diagnosis, 11.4 nM/L (x̅ 14.1; SD 11.9). Our findings demonstrated, therefore, 
that the mean cortisol level in the confirmed diagnosis group was 4.35 nM/L lower than the 
standardized morning cortisol awakening response (CAR). The limitation of small sample size 
combined with a one-time data collection may be contributing factors to the inability to report 
any significant correlations between stress and cortisol, or depression and cortisol; however, 
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study findings will inform future longitudinal research studies to examine more thoroughly the 
question of cortisol in the PCS patient population and its putative role as a mediator of stress and 
depression.  
To our knowledge no studies have been published exploring relationships between stress 
and cortisol nor between depression and cortisol in the PCS population. However, a minimal 
number of studies have been published exploring such relationships in the mTBI population. For 
example, Hutchinson et al. (2017) used a cross control repeated measures study to examine 
variables, including perceived stress and cortisol, between university athletes with concussion 
injury (n=26; men n=16, women n=10) and a healthy matched control group (n=26; men n=16, 
women n=10). Unlike our study, the researchers collected two salivary cortisol samples, one in 
the morning and one in the afternoon, at three separate time points; during the first week of 
injury (Time 1), at resolution of concussive symptoms (Time 2), and when medically cleared to 
return to play (Time 3). At time 1, mean cortisol in the athletes with concussion was reported as 
0.17 μg/dL (4.69 nM/L); time 2 mean cortisol was reported as 0.20 μg/dL (5.52 nM/L); and at 
time 3, mean cortisol was reported to be 0.18 μg/dL (4.97 nM/L) with no significant differences 
between this group and the matched control group (P > 0.44). Cortisol levels as reported by 
Hutchinson et al. (2017) were not mean CAR levels, but rather mean levels of samples collected 
at two time points, morning and afternoon. Because of this, we are unable to reliably compare 
our cortisol study findings, nor are we able to assess Hutchinson et al.’s (2017) cortisol levels for 
normality. Interestingly, Hutchinson et al. (2017) found a significant correlation between Time 1 
stress scores and salivary cortisol levels (p =0.007) in the concussion group as compared to 
healthy controls; however, they did not report such correlations for times 2 and 3. The mean time 
from beginning of data collection (time 1) to return to play (time 3) was 35 days (range 9 to 142 
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days) for the concussed athletes. Despite this individualized variance in time between injury and 
return to play; there was little variation in mean cortisol levels between data collection time 
points indicating cortisol may not mediate symptoms in this population. Hutchinson et al. (2017) 
noted that the correlation of stress and cortisol in their study sample may have indicated cortisol 
as a potential diagnostic biomarker for those concussed athletes with persistent physical 
symptoms of stress (pE46). Additionally, when considering that a diagnosis of PCS is received if 
symptoms persist beyond 90 days, the wide range of time between injury and return to play as 
reported in this study suggests ‘recovery’ from concussion injury is an individual process that 
places some individuals at risk for the development of chronic symptoms, e.g. PCS, after injury. 
When exploring relationships between perceived stress and cortisol, and depression and 
cortisol; Bay et al. (2005) reported an absence of significant relationships between variables. Bay 
(2005) collected four salivary cortisol samples (8 a.m., 12 p.m., 4 p.m. and 8 p.m.) from a sample 
of n=50 (N=53) subjects with mild to moderate TBI on a single day. The authors reported an 8 
a.m. salivary cortisol mean level of  0.59 ng/ml with a range of 0.02 to 2.87 ng/ml (1.63 nM/L; 
range 0.06 to 7.92 nM/L). This morning value is 11.42 nM/L below the standardized normal 
mean value for the CAR. This data suggests the presence of hypocortisolemia in this mild to 
moderate TBI population similar to findings in our study sample. Cortisol levels as reported by 
Bay et al. (2005) seemed to demonstrate a diurnal pattern with the 12 p.m. mean cortisol level 
reported as 0.29 ng/ml (0.8 nM/L), 4 p.m. mean cortisol level of 0.21 ng/ml (0.58 nM/L) and 8 
p.m. mean cortisol level of  0.17 ng/ml (0.47 nM/L), thus contributing to the reliability and 
validity of their reported study findings. Nevertheless, the authors noted that the use of 
antidepressants may have confounded cortisol results as approximately 43% of their study 
participants reported being diagnosed with depression and 41% reported taking antidepressant 
69 
 
 
medications. In our study, we found similar results with more than half (n=9) of the study sample 
being diagnosed with depression and/or anxiety and taking antidepressants and/or anxiolytics.  
In a longitudinal study comparing biological (heart rate variability, cortisol) and 
nonbiological (depression, anxiety) variables in a sample of individuals diagnosed with mTBI 
(N=331; men n=131, women n=200) and a healthy control group with no history of head injury 
(N=152; men n=47, women n=105), Sung et al. (2016) collected data at baseline (time of injury) 
and 6 weeks later (time 2) for the mTBI group and baseline only for the healthy control group. 
At baseline the researchers reported median serum cortisol levels in the mTBI sample as 10.66 
μg/dL (294 nM/L) and 9.65 μg/dL (296 nM/L) at week six. as compared to healthy controls 
10.88 μg/dL (300.14 nM/L) at baseline. The difference between cortisol levels at baseline was 
minimal at only 6.14 nM/L between groups. Because the time of cortisol collection was not 
reported and seemed to be random, we are unable to make reliable comparisons between the 
cortisol levels found in our study sample with those of Sung et al.(2016); however, levels as 
reported by these authors appeared to be above the normal CAR value. When considering the 
nonbiological variables, Sung et al. (2016) reported finding significantly greater levels of 
depression in the mTBI group as compared to the healthy control group at weeks 1 (p=0.002) 
and 6 (p<0.001) but reported no statistically significant correlations between depression and any 
other variable in their study, including cortisol levels. Such findings indicate a potential risk for 
the development of depression in persons after mTBI and thus contribute to a risk for developing 
PCS. In summary, other researchers, with the exception of Sung et al. (2016), have 
predominantly reported lower cortisol levels in persons with mTBI and TBI, which aligns with 
our study findings. In the current study, abnormal cortisol levels may imply a dampened CAR in 
those with a confirmed diagnosis (n=10) of PCS; indicating potential HPA axis dysfunction. We 
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suggest comparative research studies across TBI, mTBI and PCS populations to examine the 
impact of stress on HPA axis function as related to diurnal patterns and potential dysfunctional 
cortisol production would potentially contribute meaningful insights into the underlying 
mechanisms that may or may not lead to the development of PCS. This includes considerations 
regarding the role of inflammation in the development of PCS. For example, it is understood that 
cortisol shares a relationship with the inflammatory response and that inflammation occurs in 
response to activation of the HPA axis (i.e., stress response) (Glaser & Kiecolt-Glaser, 2005; 
Mavroudis, Corbett, Calvano, & Androulakis, 2015). Higher levels of inflammation in the acute 
period of TBI have been suggested to contribute to the development of PCS (Topolovec-Vranic 
et al., 2011; Rathbone, Tharmaradinam, Jiang, Rathbone, & Kumbhare, 2015). Additionally, the 
inflammatory process has  been associated with depression (Felger & Lotrich, 2013; Miller & 
Raison, 2016), and while in our study cortisol was not found to mediate a relationship between 
perceived stress and depression in the PCS sample, perhaps there are other biological indicators 
that intersect with, or are influenced by the presence of cortisol that lead to an inflammatory 
process. Therefore, comparative studies across the TBI, mTBI and PCS would further the science 
by also examining HPA axis dysfunction and biomarkers of inflammation including pro- and 
anti-inflammatory cytokines and C-reactive protein (CRP) and potential relationship to 
symptomology. From a biobehavioral perspective, enhancing our understanding of underlying 
mechanisms and their relationship to symptom development in the PCS patient population 
provides opportunities for developing and exploring potential benefits of targeted symptom 
management interventions. 
Secondary Findings 
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The Rivermead Postconcussion Symptom Questionnaire (RPQ) (King, Crawford, 
Wenden, Moss, & Wade, 1995), a measure of PCS symptoms, was used to explore the symptom 
characteristics reported by the study sample. The RPQ is a questionnaire where participants rate 
the presence of a symptom in the past 24 hours relative to the presence of the same symptom 
prior to the injury that led to a diagnosis of PCS. Scores range from 0 (not experienced at all) to 
4 (a severe problem). In the current study, an unexpected finding from data collected with the 
RPQ was the identification of ‘fatigue’ and ‘forgetfulness’ as the most problematic post-injury 
symptoms (as compared to before injury) reported by this sample, with a mean value of 3.1 for 
each of the variables. Ten of the 17 study participants reported fatigue as a severe problem (rated 
a ‘4’); n=3 rated it a moderate problem (rated a ‘3’) and n=2 a mild problem (rated a ‘2’). Only 
two subjects rated fatigue as no problem or no more of a problem than prior to injury. The 
second most common post-injury symptom reported was forgetfulness, with n=8 reporting it as a 
severe problem, n=6 as a moderate problem and n=2 as a mild problem. One study participant 
reported forgetfulness as no problem. Depression was reported to be a less problematic 
symptom, i.e. mild problem post-injury (x̅ 2, SD 1.1) in both the diagnosed and non-diagnosed 
study participants, even though, the CES-D and PROMIS ED-Depression SF scores indicated the 
presence of moderate to severe depression in this study sample.   
 Fatigue is a subjective symptom, defined as a lack of energy that ranges between feeling 
‘tired’ to feeling ‘exhausted’, that interferes with daily activity and function (Ameringer et al., 
2016; Ream & Richardson, 1996). Forgetfulness, defined as poor memory, is a complex concept 
related to cognitive dysfunction (Dwyer & Katz, 2018; Wilson, Evans & Williams, 2008). 
Following the impact of a TBI, difficulties with memory are typically related to learning and 
remembering new facts or experiences and may include reports of the loss of knowledge related 
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to facts and experiences that were known prior to the head injury (Wilson, Evans & Williams, 
2008). Both fatigue and memory disturbance are common sequelae after TBI, regardless of 
severity of injury (Cronin & O’Loughlin, 2018; Rabinowitz & Levin, 2014). It is estimated that 
as many as 70% of persons with TBI experience fatigue (Bay & Xie, 2009; Wayne, & Shinakee, 
2013). Approximately 65% of persons with TBI will experience chronic cognitive dysfunction, 
including impaired memory (Rabinowitz & Levin, 2014).   
Less is known regarding the prevalence of these symptoms in persons diagnosed with 
PCS. In a study of N=91 (men n=47, women n=44) persons diagnosed with PCS who were 
patients at a university concussion clinic, Baker et al. (2012) reported approximately 70% of 
participants identified fatigue and 95% identified concentration or memory problems as a chronic 
symptom after injury. In a longitudinal descriptive study of N=110 (men n=60, women n=50) 
persons diagnosed with PCS, Hiploylee et al. (2017) divided subjects into two groups; those who 
recovered from PCS, meaning they were no longer experiencing symptoms (n= 30) and those 
who did not recover from PCS (n=80), meaning persons continued to report symptoms. Of the 
sample that did not recover, the three highest reported symptoms in order of prevalence were 
headache, difficulty concentrating, and fatigue; with 52.5% reporting experiencing fatigue and 
67.5% reporting difficulty concentrating as chronic symptoms since time of injury. The authors 
further noted that headache was the highest reported symptom among study participants (68.8%) 
who did not recover from PCS. In contrast to these two studies, we reported fatigue and 
cognitive dysfunction as the ‘more problematic’ prevalent symptoms. Although not measured as 
variables in the current study, and based on comparative study findings, future research studies 
that include a measure of pain, fatigue and cognitive dysfunction in conjunction with measures 
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of depression may contribute to moving the science forward by examining potential relationships 
among these symptoms in comparative studies of persons diagnosed with TBI, mTBI and PCS. 
Additional Considerations 
Every effort was made to reduce participant burden in this study by including brief yet 
valid and reliable measures; however, it seems that some burden still occurred. The study 
protocol required participants to complete an IRB-formatted seven-page consent, after which 
data was collected using a one-page demographic form with a one to three page medical and 
health history (depending on the extent of medical history). Participants were asked to list 
medical and/or psychiatric illnesses that they had experienced and to list current medications 
including medication name, dosage, frequency, date prescription began, and purpose for which 
prescription was received. Of the total sample (N=17),  n=3 subjects reported no history of 
illness; n=4 reported no use of medications; n=11 (65%) reported having three or more medical 
and/or psychiatric illnesses and/or prescribed three or more medications. Some participants 
verbalized that reading the consent for understanding and completing the demographic and 
medical history forms were cognitively demanding. Such complaints seem reflective of reported 
post-injury symptoms of fatigue and cognitive dysfunction and may have influenced participant 
response on the remaining self-report data collection instruments (RPQ; PSS; CES-D; PROMIS 
ED-Depression SF), that, when taken together comprised a total of 54 items. 
In summary, these unexpected secondary study findings may be clinically meaningful as 
it is unclear what impact the post-injury symptoms of fatigue and cognitive dysfunction may 
have had on individual performance when completing study measures. Further, it is unknown 
whether such symptoms may have contributed to compromised compliance with study protocol, 
specifically the collection of a morning salivary cortisol sample within 7-days of completing the 
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paper measures. When designing future studies, it is important to consider the impact of these 
symptoms on study participation, with thoughtful efforts made to streamline and simplify the 
data collection process in this population. 
Study Strengths & Limitations 
Study Strengths 
The reliability of study measures was a strength to this study. The RPQ was scored with a 
total summed score along with the recommended method of scoring in two parts in order to 
thoroughly analyze and report the reliability of this measure in this sample. When evaluating 
reliability of the summed score, the measure performed well with a Cronbach’s alpha of 0.96 for 
both the total sample and the sample with confirmed diagnosis; and a Cronbach’s alpha of 0.95 
for the sample with unconfirmed diagnosis. When scoring in two parts, the first three items 
which relate to early presenting symptoms of PCS (headache, dizziness and nausea, and or 
vomiting) are totaled (RPQ-3). The remaining 13 items are then totaled (RPQ-13). When 
evaluating reliability by scoring in two parts, the RPQ-3 and RPQ-13, we found the RPQ-3 
performed satisfactorily with the total sample and with the confirmed diagnosis group (α =0.70 
and 0.77 respectively). The RPQ-3 did not perform as well in the unconfirmed diagnosis group 
(α=0.45). This is likely due to the small sample size (n=7) coupled with the characteristics of the 
rated symptoms. The symptoms rated in the first three items, i.e. the RPQ-3, are typically 
experienced in the acute stage of the injury, however these symptoms may present at any time in 
the continuum after mTBI and during PCS (Eyres, Carey, Gilworth, Neumann, & Tennant, 
2005).   
The PSS-10 has been found to be reliable in the mTBI and moderate TBI populations. 
Cronbach’s alpha co-efficient for the scale has been reported by Bay, Sikorskii, & Gao (2009) as 
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0.87 when used in the TBI population, indicating high internal reliability. For the current study, 
the Cronbach’s alpha co-efficient for the scale was 0.86. Interestingly, the Cronbach’s alpha for 
those without a confirmed diagnosis was only 0.61, below the acceptable level of α=0.70.  
Perhaps the 0.61 was related to the smaller sample size (n=7) of the non-confirmed diagnosis 
group. The CES-D has been found to be reliable in the TBI population as a measure of 
depression. Cronbach’s alpha co-efficient for this scale has been reported as 0.92 in a TBI 
sample (Bay, Kalpakjian & Giordani, 2012). In our study, Cronbach’s alpha co-efficient for the 
scale was 0.92 for this sample, indicating high internal reliability. The PROMIS-ED depression 
SF has been found to have potential for reliability when used in mild, moderate and severe TBI 
populations with sensitivity for this measure reported as >0.95 (Clover et al., 2018). This short 
form has been validated in other populations. In a study assessing validity and reliability of the 
PROMIS ED-Depression SF across platforms (paper instrument, personal computer, personal 
digital assistant, and interactive voice response), Bjorner et al. (2014) found the PROMIS ED-
Depression SF to be reliable in a sample of N=923 subjects with rheumatoid arthritis, depression, 
and chronic obstructive pulmonary disease (COPD), reporting a Cronbach’s alpha of 0.95 when 
collected via paper instrument. In the current study, the Cronbach’s alpha co-efficient was 0.96, 
indicating high internal reliability. When comparing reliability of the depression measures in the 
current study, we found a significant correlation of the scores as reported on the CES-D to scores 
reported on the PROMIS-ED-Depression SF (p <0.0001) suggesting this 8-item scale may be 
just as accurate in measuring the outcome of depression as the 20-item CES-D in adults 
diagnosed with PCS, thus simplifying data collection in this population. To address concerns of 
patient burden, we recommend that future studies replicate the use of both instruments in 
comparative studies across TBI, mTBI and PCS patient populations with larger sample sizes. 
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Should study findings produce similar results, then the shorter PROMIS-ED-Depression SF scale 
could be used in place of longer measures such as the CES-D which would lower item burden 
from 54 to 34, thus addressing concerns of participant burden. 
Study Limitations 
As a feasibility study, we sought to identify best practice for successful recruitment and 
enrollment of adults with PCS. We identified challenges to enrollment including (a) potential 
study participants who were interested in participation but who lacked a medical diagnosis of 
PCS, and (b) experiencing difficulty in obtaining confirmation of PCS diagnosis by examination 
of a study participant’s medical record once they were consented and enrolled. Many persons 
who were interested in participating in the study lacked a diagnosis of PCS. In total, 36 interested 
individuals were screened for eligibility. Of those, n=9 persons did not meet this inclusion 
criteria. Those not meeting this inclusion criteria stated they did not know they had a 
concussion/mTBI and therefore either they did not seek care for the injury, did not relate the 
chronic symptoms they were experiencing directly to the injury, or did not know chronic 
symptoms could occur after mTBI. These study findings support the challenge of describing the 
incidence of mTBI due to the failure of those experiencing an mTBI to seek care or, possibly due 
to under-reporting by clinicians (Powell et al., 2008; Setnik & Bazarian, 2007). In a retrospective 
study conducted at a level one trauma center, investigators found that approximately 56% of 
Emergency Department (ED) admissions identified by research staff as meeting the CDC 
guidelines for mild TBI were not diagnosed by ED physicians at the time of their visit (Powell et 
al., 2008). Along with lack of proper diagnosis, individuals may not seek health care due to 
uncertainty or lack of awareness of the potential problems related to mild brain injury. In a 
survey conducted to identify why individuals did not seek care for mTBI, researchers found that 
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the most common reason was simply not knowing care should be sought (Setnik & Bazarian, 
2007). In the current study, of the 25 interested persons who were screened and met eligibility, 
only 68%  (n=17) agreed to participate and were enrolled in the study. Reasons for deciding not 
to enroll included concern over the time commitment of participation and lack of financial 
incentive. One person did not give a reason for deciding against participation other than ‘just not 
interested’. Although the time commitment was clearly described in the screening script as 
approximately 60 minutes for the first visit and 5 minutes for the sample pick up (visit 2), 
concern over the issue of ‘time’ may have been related to PCS symptomology such as the 
presence of fatigue. Future studies will address recruitment challenges learned in the current 
study by adapting a medical records approach to study participant recruitment strategy rather 
than using general advertisement (self-selection). This adjustment in recruitment strategies 
would be designed to specifically target individuals diagnosed with TBI, mTBI and PCS in 
advance of activities directed at study recruitment, screening, consent and enrollment. We would 
anticipate that such a pro-active recruitment strategy could enlarge the potential sample size and 
address current study limitations. 
Diversity.  
We made every effort to address diversity in our small study sample. For example, we 
placed brochures and flyers advertising the study in clinics serving diverse and underserved 
patient populations. Additionally, those who participated in the study were asked to pass the 
advertisement to others who may be eligible to participate. The demographic characteristics of 
the study sample were similar to those studies in the mTBI and TBI population as reported by 
Bay (2012; 2005); that is, study participants were predominantly mid to upper class, married 
Caucasian females. Study recruitment strategies were initially focused on the Roanoke and New 
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River Valley area, which is reported to be predominantly Caucasian (86%) and African 
American (8%) with a population of approximately 3% Hispanic, 2% Asian and 1% other (men, 
48%; women, 52%) (US Census Bureau, 2017a). To address recruitment challenges, our efforts 
widened to include the urban setting of Richmond, which is reported to be approximately 48% 
African American, 40 % Caucasian, 7% Hispanic, 2% Asian and 3% other (men, 56%; women 
44% ) (United States Census Bureau, 2017b). 
Our study included n=14 Caucasian (82%), n=1 African American, n=1 Hispanic and 
n=1 Asian and of these, 13 were women (76%) and 4 were men. Given the demographics of 
previous studies in the mTBI and PCS populations, we predicted a larger Caucasian presence, 
but we could not predict the distribution of male to female subjects given the imbalance in male 
to female subjects reported from the literature review. The literature suggests women may be 
more likely than men to present with PCS symptomology and therefore more likely to be 
diagnosed with PCS. For example, in a study of N= 223 subjects with mTBI (n=123, men n=91, 
women n=32) or admitted with trauma (n=100, men n=64, women n=36), Ponsford et al. (2012) 
reported finding that women were 2.56 times more likely to report PCS symptoms than men. 
Additionally, in a study of N=180 (men n=115, women n=65) subjects with mTBI, Dischinger, 
Ryb, Kufera, and Auman (2009) found that 53% of the women reported PCS symptoms at three 
months after injury as compared to 33% of men sampled. Neither race nor ethnicity were 
reported in either study. When planning for recruitment in future studies, it will be important to 
consider methods for maximizing recruitment efforts to ensure a more diverse study sample. For 
example, researchers might consider reaching out to leaders of community-based organizations 
to offer educational programs to enhance awareness of the problem of concussion/mTBI and 
PCS. This strategy would not only foster awareness of the problem, but also aid in building 
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relationships and trust within diverse communities. Collaboration with healthcare providers 
serving diverse and underserved populations and with lay persons may encourage engagement of 
a diverse population. 
Singular cortisol sample. 
Collection of salivary cortisol samples over time to facilitate the evaluation of potential 
changes in cortisol in response to a stressor, or to examine diurnal patterns in cortisol levels, is 
the preferred method of sampling (Bay et al., 2009; Granger, Johnson, Szanton, Out, & 
Schumann, 2012); however, the current feasibility study protocol provided an opportunity to 
collect cortisol data at one time point, thus limiting our ability to engage study participants over 
time. In an effort to address this study limitation and to collect a reliable and valid sample of 
salivary cortisol that is limited to a one-time data point, participants in the current study were 
educated to the importance of the timing of the biologic data collection. The objective was to 
collect salivary cortisol at the known peak time point. Secretion of cortisol is diurnal, meaning 
secretion occurs episodically over a 24-hour cycle with the greatest secretion occurring 30 to 45 
minutes after waking in the morning (Kirschbaum & Hellhammer, 1989). This peak of secretion 
is referred to as the cortisol awakening response (CAR) and is considered a reliable indicator of 
HPA axis function (Kunz-Ebrecht, Kirschbaum, Marmot, & Steptoe, 2004; Wüst, Federenko, 
Hellhammer, & Kirschbaum, 2000). Adherence to the study protocol for cortisol collection was a 
threat to validity for this study. Prior to consent, the participants were asked about their concerns 
related to completing the study such as in collecting and storing the salivary sample or ability to 
be available to the investigator at the time of sample pick up. Participant concerns were 
addressed, and a plan developed with each participant for successful completion of the data 
collection process. Despite this plan, we found collection of cortisol samples to be challenging.  
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Participants were reluctant to receive morning text or email reminders. A mid-week reminder 
was negotiated with most participants for collection of the sample to occur within seven days 
from completion of the paper pencil instruments. Despite all effort, the median time of salivary 
sample collection occurred 9 days after completion of the instruments with a range of 2 to 17 
days. Two of seventeen samples were not collected due to loss of contact with subjects. 
Implications for Nursing Research 
In the US, TBI affects approximately 1.7 million individuals annually with the majority 
of injuries, nearly 75%, being classified as mTBI. Although most individuals completely recover 
from mTBI, approximately 10% will continue to report the persistent symptoms of PCS. While 
the variables of perceived stress, cortisol, and depression have reportedly been studied in the TBI 
population, there are very few studies examining these variables in persons with PCS. In an 
effort to address this gap we conducted a study using a holistic paradigm, i.e. a 
psychoneuroimmunology framework, to explore these factors in persons diagnosed with PCS.  
Given that our study findings indicated a significant relationship between perceived stress and 
depression but not between cortisol and perceived stress nor between cortisol and depression, we 
are poised to design future studies to help address our study outcomes. Within the design of 
future studies, we will take into consideration our unexpected findings of fatigue and cognitive 
dysfunction as distressing symptoms as measured by the RPQ. These findings support the current 
evidence that persons with PCS are at risk for developing depression; however, more 
comprehensive, prospective research designs are needed to contribute to our understanding of 
PCS symptomatology, including depression, fatigue, cognition, and pain as well as other factors, 
both biological and psychosocial, that have the potential to place an individual with a TBI or 
mTBI at risk for developing PCS. Non-biological factors would include self-reported levels of 
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stress, environment, family history and social support (Bay & Covassin, 2012; Dwyer & Katz, 
2018). Biological factors could include cortisol and immunological biomarkers such as pro-and 
anti-inflammatory cytokines and C-reactive protein (Barlow, 2016; Bay et al., 2005; Rathbone, 
Tharmaradinam, Jiang, Rathbone, & Kumbhare, 2015). Additionally, based on our study 
findings, participant recruitment and retention may be more successful by lessening patient 
burden through the use of valid and reliable measures that minimize patient effort. For example, 
replacing the CES-D with the brief, and easily completed, PROMIS ED-Depression SF when 
measuring depression. Further, rather than general advertising for study participants and seeking 
post-consent confirmation of a PCS diagnosis as occurred in the current study, future research 
efforts aimed at interprofessional collaboration and review of medical records for identification 
of potential eligible study participants would contribute to a stronger study design. And finally, 
to enhance diversity of sample, it is important to collaborate with racially and ethnically diverse 
multidisciplinary research teams as well as partnering with community leaders serving diverse 
populations.  
 In summary, it would seem that the perception of stress impacts the presence of 
depressive symptoms in persons experiencing PCS, however much is unknown about the impact 
of perceived stress and stressors, or the influence of other factors on the development of PCS and 
the presence of PCS symptoms. Furthermore, recovery from mTBI appears to be an idiosyncratic 
process with some persons not fully recovering and therefore at risk for diagnosis of PCS. We 
have much to learn about the underlying mechanisms behind the development of PCS and the 
occurrence of symptoms, such as depression, in this vulnerable patient population. For example, 
we do not know the influence of HPA axis dysfunction and associated alterations in cortisol 
production, nor the impact of inflammation that occurs post-injury has on the presentation of 
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PCS. Both mechanisms, HPA axis dysfunction and inflammation, have been found to be present 
in the mTBI and TBI populations, and have been associated with the occurrence of depression; 
but we do not know if or how these mechanisms influence the presentation of depression or other 
symptoms in persons with PCS. Additionally, because we do not know if stress, stressors, or any 
of the biological mechanisms that may potentially influence the development of the chronic 
symptomology of PCS that follows a mTBI, future comparative studies that examine both mTBI 
and PCS patient population are warranted. Exploring HPA axis function and inflammatory 
processes (e.g., pro- and anti-inflammatory cytokines and CRP), psychosocial and environmental 
influences and associations with currently reported symptoms can provide an opportunity to 
further inform our understandings regarding the risk for or development of PCS. When planning 
future studies that include biomarkers such as cortisol, pro- and anti-inflammatory cytokines, or 
CRP, thoughtful planning must be considered for specimen collection time points and adherence 
to specimen collection protocol to ensure complete data collection and the reliability of study 
findings. Recruitment can be a challenge in this population, therefore strategies for enrolling a 
larger, more diverse sample should be fully explored. The presentation of community education 
programs would promote awareness of the problem and may potentially increase study 
enrollment. Additionally, heightened awareness of the problem may increase the probability that 
those persons who have experienced a mTBI will seek healthcare. By further exploring and 
understanding biologic and psychosocial mechanisms and processes related to the development 
of PCS and associated symptoms, we may then better serve this population with the induction of 
nursing interventions and self-care strategies to enhance symptom management and thus improve 
quality of life. 
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Appendix A 
Conceptual Framework 
Figure A1. Biobehavioral Relationships Among Perceived Stress, Cortisol and Depression in 
Adults Diagnosed with Postconcussion Syndrome (PCS). 
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Figure A1 Biobehavioral Relationships Among Perceived Stress, Cortisol and Depression in 
Adults Diagnosed with Postconcussion Syndrome (PCS). 
 
Figure A1. Conceptual framework informed by a Psychoneuroimmunology paradigm. Adapted 
from McCain, N.L., Gray, P.G., Walters, J.M., & Robins, J. (2005). Implementing a 
comprehensive approach to the study of health dynamics using the psychoneuroimmunology 
paradigm. Advances in Nursing Science, 28(4). p. 320-332. Note mTBI= mild traumatic brain 
injury. 
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Appendix B 
Study Tables 
Table 1 PRISMA Flow Diagram 
Table 2. Literature Review Study Table  
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Table A.1 PRISMA 2009 Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching  
(n = 64) 
Additional records identified 
through other sources  
(n = 0) 
Records after duplicates removed  
(n = 29) 
Records screened  
(n = 23) 
Records excluded  
(n =16) 
n=3 dissertation  
n= 6 PTSD population  
n= 2 Subjects did not have 
documented TBI 
n=3 subjects were caregivers 
n= 2 clinical review 
 
Full-text articles assessed 
for eligibility  
(n = 7) 
Full-text articles excluded, 
with reasons  
(n = 0) 
 
Studies included in 
qualitative synthesis  
(n = 0) 
Studies included in 
quantitative synthesis  
(n = 7) 
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Table A.2 
Literature Review Study Table 
Study Study Design Participants PCS/TBI 
definition criteria 
Intervention/ 
groups 
Main Outcome 
Variable/Measures 
Findings 
Bay 2002 Non-
experimental 
cross-
sectional 
study 
Convenience 
sample of N=75 
adults (male 
n=39; female 
n=36). Recruited 
from 5 
rehabilitation 
clinics with 
diagnosis of mild 
or moderate TBI 
and evaluated by 
study 
neuropsychologist 
1993 American 
Congress of 
Rehabilitation 
Medicine  
 
(n=27 mTBI; 
n=48 moderate 
TBI) 
N/A Post-injury stress 
(PSS) 
 
Depressive 
Symptoms (NFI-D, 
CES-D)  
 
Interpersonal 
relatedness (IRI, 
Hagerty’s sense of 
belonging 
Instrument) 
The NFI-D and 
CES-D 
were strongly 
correlated (r=.85, 
p<.00, one-tailed). 
 
20% subjects had 
CES-D scores >30.5 
 
Significant 
relationship between 
PSS and depression, 
as measured by the 
NFI-D, (R2=0.54, 
F=87.72 (1, 73), 
p=0.00) 
Bay, 
Hagerty, 
Williams, 
& Kirsch, 
2005 
 
[Perceived 
stress, 
Cortisol, 
Depression 
& TBI] 
Non-
experimental 
cross-
sectional 
study 
Convenience 
sample of N=75 
adults (male 
n=39; female 
n=36). Recruited 
from 5 
rehabilitation 
clinics with 
diagnosis of mild 
or moderate TBI 
and evaluated by 
study 
neuropsychologist 
1993 American 
Congress of 
Rehabilitation 
Medicine per Bay 
et al., 2002. 
 
(n=27 mTBI; 
n=48 moderate 
TBI) 
N/A Pre-injury chronic 
stress (CAC, 
MSLEC) 
Post-injury stress 
(PSS) 
 
Salivary Cortisol 
 
Depressive 
Symptoms (NFI-D)  
 
Interpersonal 
relatedness (IRI, 
Hagerty’s sense of 
belonging 
instrument) 
 
Individuals with 
mTBI demonstrated 
greater 8 am 
salivary cortisol 
levels than those 
with moderate TBI 
(t= 2.66, df 48, 
p=0.011) 
 
8 am (t=2. 39, df 
9.23, p=0.04) and 
noon (t=2.18, df 
20.74, p=0.04) mean 
cortisol values were 
significantly greater 
for those reporting 
more pre-injury 
childhood adversity.  
 
8pm cortisol level 
associated with 
frequency of pre- 
injury stressful life 
events (r=0.38, 
p=0.01). 
 
No relationship 
between salivary 
cortisol values and 
level of depression. 
 
Limitations: Small 
sample size 
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Strom & 
Kosciulek, 
2007 
 
[Perceived 
stress, 
Depression 
& TBI] 
Non-
experimental, 
cross-
sectional 
Convenience 
sample of N=94 
subjects (male 
n=35; female 
n=58). Recruited 
from 2 
rehabilitation 
centers, with 
confirmed 
diagnosis of 
mTBI 
mTBI as evidenced 
by a Glasgow 
Coma Scale score 
of 13–15 and a 
period of post-
traumatic amnesia 
of less than 60 
minutes 
N/A Stressors (PSS) 
 
Appraisal (Hope 
scale) 
 
Coping (Problem 
solving inventory) 
 
Stress 
response/depression 
(BDI) 
 
Adjustment 
(Productivity scale 
of the Community 
Integration 
Questionnaire, 
Satisfaction with 
Life Scale) 
PSS scores ranging 
from 10-50 with a 
mean score of 28.8  
 
BDI mean 
depression scores 
ranging from 0-63 
with a mean score of 
16.7  
 
statistically 
significant (β=0.67; 
p< 0.001) 
correlation between 
the levels of 
perceived stress 
scores and 
depression scores  
Bay & 
Donders, 
2008 
 
[Perceived 
stress, 
Depression 
& TBI] 
 
Non-
experimental 
cross-
sectional 
study  
Convenience 
sample of N=84 
adults (male 
n=43; female 
n=41). Recruited 
from eight 
rehabilitation 
centers with 
diagnosis of mild 
or moderate TBI.  
Diagnosed TBI 
 
(n=65 mTBI; 
n=19 moderate 
TBI) 
N/A Chronic Stress (PSS, 
Impact of event 
scale-revised) 
 
Depressive 
Symptoms (NFI-D) 
 
Somatic symptoms 
(McGill pain 
questionnaire, 
modified version of 
the fatigue impact 
scale) 
Functional status 
(30-item PCRS) 
Pain (MPQ-SF) 
Fatigue (POMS-F) 
NFI-D scores 
ranged from 13-56 
with a mean score of 
31.71, 58% (n=49) 
of subjects reported 
a score >28, and 
42% (n=35) 
reported scores <28  
 
For those subjects 
categorized as 
depressed (NFI-D 
score >28), the 
mean PSS score was 
27.37. 
 
 For those subjects 
categorized as not 
depressed (NFI-D 
<28), the mean PSS 
score was 19.66.  
 
No significant 
relationship was 
reported between 
levels of fatigue and 
depression or levels 
of pain and 
depression; 
however, levels of 
perceived stress 
were evidenced to 
explain levels of 
depression 
(R²=0.55)   
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Bellon, et 
al., 2015  
 
[Perceived 
stress, 
Depression 
& TBI] 
 
 
Experimental 
RCT, cross 
over design 
Purposive sample 
of  N=123 adults 
with n=69 
completing all 
time points 
(male n=41; 
female n=28). 
Recruited from 
community and 
from Northern 
California TBI 
model Systems 
database with 
history of TBI. 
Diagnosed TBI 
 
(n=10 mTBI; n=10 
moderate TBI; 
n=35 severe TBI; 
n=13 unknown) 
12-week 
walking 
intervention 
(n=28) 
Week one-
tracked their 
activity as 
usual with 
pedometer. 
Each week 
after, increase 
steps by 5% 
until week- 8, 
then maintain 
the daily level 
of steps for 
weeks 9-12. 
Coaching 
three times a 
week for 
weeks 1-3 
then twice a 
week for 
weeks 4-8. 
Coaching 1- 
time a week 
for weeks 9-
12. 
 
12-week 
attention 
control 
nutrition 
education 
program 
(n=39) 
Coaching on 
same 
schedule as 
intervention 
group 
 
Measures 
collected at 
baseline, 12- 
weeks, and 
24- weeks 
Depression (CES-D) 
 
Perceived stress 
(PSS) 
 
Mean CES-D score 
of 16 for both 
groups at baseline,  
 
At 12 weeks, the 
walking group 
reported a mean 
CES-D score of 12 
as compared to the 
nutrition group 
mean score of 15  
 
At 24 weeks, both 
groups reported a 
mean score of 13 
(p=0.007).  
 
Mean PSS score of 
25 at baseline for 
the walking group 
and 23 for the 
nutrition education 
group.  
 
At 12 weeks, the 
PSS mean score of 
20.76 for the 
walking group 
compared to the 
nutrition education 
group mean score of 
24.3.  
 
At 24 weeks, the 
PSS mean score for 
both groups were 
reported as 21.  
 
The authors reported 
significant decreases 
in PSS scores during 
the walking 
intervention for both 
groups (p=0.006) 
with a significant 
decrease in PSS 
score at 24 weeks 
for both groups 
(p=0.006).  
. 
Limitations: attrition 
rate of 50% 
Luo, Chai, 
Jiang, 
Chen, & 
Yan, 2015 
Quasi-
experimental 
longitudinal 
interventional 
Convenience 
sample of N=68  
adults (male 
n=45; female 
Diagnosed TBI on 
admission to 
hospital. 
 
Group 1: 
 6-week 
Psychotherap
y  
Severity of Injury 
(GCS) 
 
Chronicity (GOS) 
n=32 subjects 
demonstrated 
hypocortisolemia 
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[Cortisol, 
depression, 
TBI] 
Study using  
comparison 
groups 
 
stratified 
according to 
cortisol 
 
n=23) Recruited 
from 
neurosurgical 
department of a 
University 
hospital with 
diagnosis of 
depression or 
depressive 
symptoms 
Severity classified 
by GCS on 
admission 
. 
3-8: severe 
9-12: moderate 
13-15: mild 
 
Mild TBI defined 
by the ACRM. 
(N=68) 
 
Group 2: 
Psychotherap
y and 
Citalopram 
(n=28) 
 
Group 3: 
Psychotherap
y Citalopram 
and 
Prednisone 
(n=32) 
 
N=8 
recovered 
post 
psychotherap
y; not 
assigned to 
pharmacother
apy groups 
 
Cortisol (denote 
when measured) 
 
Depression (BDI-II) 
(measured baseline; 
6 weeks; 9 weeks) 
and were placed in 
group 3.  
 
No significant 
correlation between 
severity of injury 
and severity of 
depression (r=0.128, 
p>0.05).  
 
Group 1: absent 
depressive 
symptoms after 
treatment. 
Group 2: n=27 
subjects reported 
decreased/absent 
depressive 
symptoms after 
treatment 
Group 3: n=30 
subjects reported 
decreased/absent 
depressive 
symptoms after 
treatment 
 
Limitations: Lack of 
control, no statistical 
analysis of effect 
among the 3 groups. 
Cortisol levels and 
demographic 
information not 
reported. 
 
  
Sung et al., 
2016 
 
[Cortisol, 
depression, 
TBI] 
Longitudinal  
comparison 
group design 
Non-
experimental 
Comparative 
study 
Prospective 
Chapter 9 
118= 
Convenience 
sample of N=483 
adults (male 
n=178; female 
n=305). Recruited 
from a University 
hospital with a 
diagnosis of 
mTBI. Healthy 
controls with no 
history of TBI. 
Diagnosed by 
medical provider. 
 
World Health 
Organization 
definition of mTBI. 
mTBI group: 
n=331 
 
Healthy 
control 
group: n=152 
Neurohormones 
(ACTH, IGF-1, 
melatonin, cortisol) 
 
HRV 
 
Anxiety: BAI 
Depression: BDI-II 
Greater report of 
anxiety in mTBI 
group as compared 
to healthy controls 
at 1 week (p<0.001) 
and 6 weeks 
(p<0.05). 
 
Greater report of 
depression in the 
mTBI group 
compared to the 
healthy controls at 1 
week (p=0.002 and 
6 weeks (p<0.001). 
 
No statistically 
significant change in 
cortisol levels from 
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week 1 and week 6 
in mTBI group. No 
statistically 
significant 
differences in 
cortisol levels 
between groups 
(p=0.698). 
 
Did not compare 
cortisol to 
depression 
 
Limitations: loss of 
125 mTBI subjects 
from week 1 to 
week 6 due to 
subjects not 
following up at 
hospital. Unequal 
number of male to 
female subjects. 
Healthy control 
group was younger 
than mTBI group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
 
Appendix C 
Recruitment Material 
 
1. Newsletter Advertisement Roanoke and New River Valley  
2. Newsletter Advertisement Richmond 
3. Study Flyer Pull-off Roanoke and New River Valley  
4. Study Flyer Pull-Off Richmond 
5. Study Flyer Publisher 
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Newsletter Advertisement Roanoke and New River Valley 
Hardcopy and Online 
Postconcussion Syndrome Study 
 
If you are age 21 or over, and have a diagnosis of Postconcussion syndrome, you may qualify to 
participate in a research study conducted in the Roanoke and New River Valleys. Participants of 
this study will be asked to meet two times in a private area to protect confidentiality. Once to 
meet with the student investigator to complete four sets of questionnaires and receive a kit for 
collection of a sample of saliva for purposes of measuring a stress biomarker. A second shorter 
meeting will be required to pick up the sample of saliva. Compensation is available at 
completion of the study. For more information, please contact: 
 Christine Huson, MSN, RN  
Doctoral student Virginia Commonwealth University 
 (540) 985-4028 or email husonc@vcu.edu. 
 
Principal Investigator:  
Victoria Menzies PhD, RN, PMHCNS-BC, FAAN 
Associate Professor Virginia Commonwealth University 
VCU IRB #HM20009108  
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Newsletter Advertisement Richmond 
Hardcopy and Online 
Postconcussion Syndrome Study 
 
If you are age 21 or over, and have a diagnosis of Postconcussion syndrome, you may qualify to 
participate in a research study conducted in the Richmond, Va. area. Participants of this study 
will be asked to meet two times in a private area to protect confidentiality. Once to meet with the 
student investigator to complete four sets of questionnaires and receive a kit for collection of a 
sample of saliva for purposes of measuring a stress biomarker. A second shorter meeting will be 
required to pick up the sample of saliva. Compensation is available at completion of the study. 
For more information, please contact: 
 Christine Huson, MSN, RN  
Doctoral student Virginia Commonwealth University 
 (540) 985-4028 or email husonc@vcu.edu. 
 
Principal Investigator:  
Victoria Menzies PhD, RN, PMHCNS-BC, FAAN 
Associate Professor Virginia Commonwealth University 
VCU IRB #HM20009108  
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Study Flyer Pull-off Roanoke and New River Valley  
 
 
Adult Volunteers with Postconcussion Syndrome Sought for Research Study 
 
Adult Volunteers with Postconcussion Syndrome Sought for Research Study 
 
The purpose of the study is to explore the relationship between stress, cortisol as a 
biomarker of stress, and depression in adults age 21 and over, who are diagnosed with 
postconcussion syndrome or PCS.  This study involves completing four sets of 
questionnaires and providing one sample of saliva. Volunteers will be asked to meet two 
times. One time to complete a set of four questionnaires and receive a kit for collection of 
a sample of saliva  which should take no longer than 60 minutes, and one time for 
collection of the saliva sample which should take no longer than 5 minutes. This study is 
being conducted in the Roanoke and New River Valleys 
 
 Compensation is available at study completion. 
 
Contact Information: 
For more information please contact: 
o Christine Huson MSN, RN 
o Doctoral student Virginia Commonwealth University 
o By phone at (540) 985-4028 
o Or by email at husonc@vcu.edu  
 
 
Principal Investigator: Victoria Menzies PhD, RN, PMHCNS-BC, FAAN 
Associate Professor Virginia Commonwealth University 
           VCU IRB #HM20009108  
  
Contact information tear-off flags (as shown below) are optional. 
o   
 
 
Principal Investigator: Victoria Menzies PhD, RN, PMHCNS-BC, FAAN 
 
Contact information tear-off flags (as shown below) are optional. 
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Study Flyer Pull-Off Richmond 
Adult Volunteers with Postconcussion Syndrome Sought for Research Study 
 
The purpose of the study is to explore the relationship between stress, cortisol as a 
biomarker of stress, and depression in adults age 21 and over, who are diagnosed with 
postconcussion syndrome or PCS.  This study involves completing four sets of 
questionnaires and providing one sample of saliva. Volunteers will be asked to meet two 
times. One time to complete a set of four questionnaires and receive a kit for collection of 
a sample of saliva  which should take no longer than 60 minutes, and one time for 
collection of the saliva sample which should take no longer than 5 minutes. This study is 
being conducted in the Richmond area. 
 
 Compensation is available at study completion. 
 
Contact Information: 
For more information please contact: 
o Christine Huson MSN, RN 
o Doctoral student Virginia Commonwealth University 
o By phone at (540) 985-4028 
o Or by email at husonc@vcu.edu  
 
 
Principal Investigator: Victoria Menzies PhD, RN, PMHCNS-BC, FAAN 
Associate Professor Virginia Commonwealth University 
                                               VCU IRB #HM20009108  
  
Contact information tear-off flags (as shown below) are optional. 
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Study Flyer Publisher 
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Appendix D 
1. Telephone Interview Script 
2. Participant Tracking and Screening Form 
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Telephone Interview Script  
Thank you for calling the VCU School of Nursing Postconcussion Syndrome Study. This is 
[Your Name], how can I help you?  
 
Then go to this script: 
 
Thank you for your interest in this study. May I have your name? Thank you, and may I ask 
how you heard about this study? Great. 
  
I’d like to tell you a bit about the study. In the past decade there have been many advances in our 
understanding of concussion and mild traumatic brain injury. These advances have led to 
improvements in preventive measures such as concussion screening, patient education after 
concussion and mild traumatic brain injury and sports related improvements such as shock 
resistant football helmets; however we do not know exactly what causes those individuals who 
suffer a mild brain injury to develop persistent symptoms of PCS [you may have to explain that 
this is the acronym for the longer term] or why one person might experience symptoms such as 
depressed mood while others do not.  We don’t know if factors such as how people experience 
stress or how the release of a stress hormone might have an effect on symptoms such as 
depressed mood.  
 
This study is being conducted to learn more about the relationship between perceived stress; 
cortisol, a hormone related to stress; and symptoms such as distressed mood that might occur 
among individuals with a diagnosis of PCS. To better understand a possible relationship between 
these variables, we are inviting adults age 21 and older, who have been diagnosed with PCS to 
participate in this study 
  
[Involvement] 
Generally, participation in the study involves you meeting with me to complete a consent process 
and to provide you with the opportunity to ask questions that we might answer for you. This may 
be done in your home or at another place that is comfortable to you yet offers privacy so that any 
information you provide remains confidential. Once we have met, and if you consent to 
participate in this study, all of the information I obtain will remain confidential, and will be 
identified by a number only. At that time, I will ask if you would be interested in further studies 
related to individuals with postconcussion syndrome. If you agree to be contacted for future 
studies, only your preferred contact information will be kept. 
 
During your study appointment and after you have agreed and consented to participate, you will 
be asked to complete questions related to your health history and demographic background.  
Following this, you will be asked questions regarding how you think about or experience stress 
as well as questions related to any feelings of sadness or depression you might have experienced 
in the past week. For example, you will be asked to rate how often "In the past week [you] felt 
depressed". . You may choose not to answer questions about which you are uncomfortable. 
 
Also, during our first study appointment and after you have agreed and signed an informed 
consent form to participate in the study, we will ask you to provide proof of your diagnosis of 
PCS with either a note from your primary healthcare provider or a print out of your medical 
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records.  If that is not possible, we will ask you to complete a diagnosis confirmation form to 
enable us to contact your primary health care provider to confirm your diagnosis of PCS. A copy 
of this form will be provided to you. 
 
Following this initial study visit, there will be one more step to the collection of data and that 
would be asking you to collect a sample of your saliva during the following week (within 7 days) 
of your first study visit. This one extra step will involve asking you to collect a sample of your 
saliva, using a simple cotton tip swap and storing it until we can retrieve it.  We provide all the 
needed materials and instructions so as to keep it as simple as possible for you.  We will use this 
saliva to analyze a stress hormone called cortisol.  Our study plan is to compare the level of this 
stress hormone in your body to the answers you provide on the questionnaires we will be giving 
you.  At the time of the first meeting, I will provide you with a saliva collection kit as well as 
with detailed written directions on how to collect and store your saliva.  Following this, you and 
I, together, will make a plan for how I may retrieve this sample from you.  I will explain this in 
more detail if you are eligible and choose to participate in this study. 
 
All levels of participation in this study are completely voluntary.  I will explain each of the tasks 
in more detail at the time of our meeting.   
 
There is no cost to you to participate, other than the time you spend completing the study.  Study 
participants will be compensated for their time.  Upon completion of all study-related requests, 
and after I retrieve your saliva sample, you will be provided with a 10 dollar Walmart gift card.   
 
We hope that the information gained by your participation will provide insight into how the 
experience of stress may influence mood in adults diagnosed with PCS.  
 
Are there any questions I can answer for you? 
 
NEXT:  
 
If participant is interested, then the next step is to inform them that in order to be considered to 
be in the study, you need to ask them a few questions first.   
If Participant states they are not interested: We want to thank you for your call and for the 
time you took to have this explained. Should you change your mind, or want more 
information, feel free to contact me at this number.  Once again, thank you. . 
 
Are you age 21 or older?  If no, then ineligible. Stop the interview and thank them for 
calling.  
 
Are you currently pregnant?  If “yes” then ineligible – stop the interview and say “It is one of 
our criteria that we can’t include pregnant women in this study but thank you for your 
interest. 
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Have you been diagnosed with a severe psychiatric condition?  If person says they were 
hospitalized once for having had a break down, simply ask them what the diagnosis was 
that brought them to the hospital.  If anxiety or depression or general admission then okay. 
 
Are you able to obtain and bring with you to the first meeting a note from your MD confirming 
your diagnosis of Postconcussion Syndrome?  If yes, please bring this confirmation with you to 
your first study visit, should you decide to participate.  
 
You may ask them how they will do this and/or offer the following advice: “All you need to 
do is call your provider’s office and ask them to document your official PCS diagnosis on a 
prescription form and leave it for you to pick up in an envelope at the reception desk. 
There should be no need to make an appointment. Then just pick it up and bring it with 
you to your first study visit. WE WILL SO APPRECIATE THAT!” 
 
If interested and meet inclusion criteria, proceed to enrollment form 
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Participant Tracking and Screening Form 
IID _______ 
EID _______ 
SID ______ 
Participant Interest Tracking Form 
Menzies/Huson   IRB# HM20009108 
 
Response to Advertisement (Interest ID) Form 
 
Message Received Date: __________ Time: _______ PD: _______ Interest ID# (IID):_______    
 
Contact Method (circle one):   Phone     Email  
 
If email contact: 
First attempt: 
PD email response sent (Date): ____________ Time: _________ 
Reply email with phone # received (Date): __________ Time: ________  
No reply email received:  no response (nr) 
 
Second attempt (if necessary) 
PD email response sent (Date): ____________ Time: _________ 
Reply email with phone # received (Date): __________ Time: _________    
No reply email received:  no response (nr) 
 
If phone contact: 
First attempt: 
PD call back (Date): ______________   Time: _________ 
Outcome (circle one):   reached person left message 
If reached person, continue to screening form below: 
 
Second attempt: 
PD call back (Date): ______________   Time:________ 
Outcome (circle one):   reached person left message 
If reached person, continue to telephone script.: 
 
How did the individual hear/read about the study?_____________________ 
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Enrollment Form 
If eligible, Eligibility # (EID): __________ 
 
Study appointment information: 
 
Initial Baseline Visit: 
 
Appointment Date____________    Time ________________     Location _________________ 
 
Salivary Data Collection Visit: 
 
Appointment Date____________    Time ________________     Location ________________ 
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Appendix E 
1. Study Consent Form 
2. Stand-alone HIPAA Form 
3. Diagnosis Confirmation Note 
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Study Consent Form 
 
RESEARCH SUBJECT INFORMATION AND CONSENT FORM 
 
TITLE: Perceived Stress, Salivary Cortisol and Depression in Adults with Postconcussion 
Syndrome; A Pilot Study 
VCU IRB NO.: #HM20009108 
 
INVESTIGATOR: Victoria Menzies, PhD, RN, PMHCNS-BC, FAAN 
STUDENT INVESTIGATOR: Christine Huson, MSN, RN 
 
This consent form contains important information to help you decide whether to take part in a 
research study. The student investigator will explain this study to you. If any information 
contained in this consent form is not clear, please ask the student investigator to explain any 
information that you do not fully understand. You may take home an unsigned copy of this 
consent form to think about or discuss with family or friends before making your decision. 
Please keep in mind: 
 Being in a study is voluntary- your choice. 
 If you join this study, you can still stop at any time. 
 No one can promise that a study will help you.  
 Do not join this study unless all of your questions are answered. 
 
After reading and discussing the information in this consent form you should know: 
 Why this research study is being done; 
 What will happen during the study; 
 Any possible benefits to you; 
 The possible risks to you; 
 Other options you could choose instead of being in this study;  
 How your personal health information will be treated during the study and after the study 
is over; 
 Whether being in this study could involve any cost to you; and 
 What to do if you have problems during the study or questions about this study. 
 
Please read this consent form carefully. 
 
PURPOSE OF THE STUDY  
The purpose of this research study is to learn more about the relationships between perceived 
stress; cortisol, a hormone related to stress; and symptoms such as distressed mood that might 
occur among persons with a diagnosis of postconcussion syndrome, also known as PCS. To 
better understand a possible relationship between these variables, we are inviting adults 21 years 
of age and older, who have been diagnosed with PCS to participate in this study. There will be 
up to 60 adults (male and female) from the Roanoke and Richmond, Virginia area who will be 
participating in this study. You are being asked to participate in this study because you are an 
adult who has been diagnosed with postconcussion syndrome.   
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DESCRIPTION OF THE STUDY AND YOUR INVOLVEMENT 
If you decide to be in this research study, you will be asked to sign two copies of this consent 
form after you have had all your questions answered and understand what will happen to you 
during the study. One copy of this informed consent will be given to you and one retained by the 
PI. After you have agreed and signed the informed consent forms to participate in the study, you 
will be asked to provide proof of your diagnosis of PCS with either a note from your healthcare 
provider or a print out of your diagnosis from your medical records. If that is not possible, you 
will be asked to sign diagnosis confirmation form permitting the student investigator to ask your 
healthcare provider for confirmation of PCS diagnosis. If contacting your provider, we will make 
a copy of the diagnosis confirmation document that you have signed and we will send it to your 
identified healthcare provider with a letter from us asking for confirmation of a diagnosis of 
PCS. If you agree to participate in this study and after you have signed the informed consent 
forms, you will be assigned an identification number to which all of your information will be 
confidentially linked.  
 
Volunteers who agree to participate in this study will be asked to meet two times for study 
appointments. The first study appointment will take approximately 60 minutes and the second 
study appointment approximately 5 minutes. 
 
During your first study appointment and after you have agreed and signed an informed consent 
form to participate in the study, you will be asked to complete questions related to your health 
history and demographic background. You will be then be asked questions regarding how you 
think about or experience stress as well as questions related to any feelings of sadness or 
depression you might have experienced in the past week. For example, you will be asked to rate 
how often "In the past week [you] felt depressed". You may choose not to answer questions 
about which you are uncomfortable. 
 
Following this initial study appointment, there will be one more step to the collection of data and 
that would be asking you to collect a sample of your saliva during the following week (within 7 
days) of your first study appointment. This one extra step will involve asking you to collect a 
sample of your saliva, using a simple cotton tip swap and storing it until we can retrieve it. We 
provide all the needed materials and instructions at your first study appointment so as to keep it 
as simple as possible for you. We will ask you to collect a one-time sample of your saliva 30 
minutes after you wake up in the morning. Because this sample is to collect a hormone related to 
stress that is present in saliva, we will ask that you collect the sample after a normal or routine 
evening and night of sleep. We will arrange with you to send a text or phone reminder to help 
you remember to collect this. After you collect the saliva sample, we will ask that you apply a 
label recording the date and time of collection only. You will place the swab of saliva sample in 
the bag that will come with the pre-assembled kit and once sealed, place in a safe space in your 
home freezer. After you collect the sample of saliva, we ask that you notify the student 
investigator at a designated, confidential telephone number that we will provide. We will work 
with you at that time to arrange a convenient time for retrieving this sample from you.   
 
We will use this saliva to analyze a stress hormone called cortisol. Our study plan is to compare 
the level of this stress hormone in your body to the answers you provide on the questionnaires 
we will be giving you. 
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RISKS AND DISCOMFORTS 
We do not expect anyone to be harmed by this study any more than they would be in daily life. 
There may, however, be some brief discomfort when answering questions about stress or 
feelings related to mood. Some of the questions you will be asked are personal and could make 
you feel uncomfortable. If there are questions that you do not wish to answer, you may skip 
those questions. There is also a potential risk for loss of confidentiality. We will minimize this 
risk be storing your data and samples as securely as possible.  
 
BENEFITS TO YOU AND OTHERS 
This is not a treatment study and you may not get any direct benefit from participating in this 
study. The information we gain from this study will not have a direct effect on you. The 
information learned in this study may benefit others diagnosed with PCS in the future as study 
findings may help us to better understand how perceptions of stress or release of the hormone 
cortisol affect feelings such as depressed mood in people with PCS. 
 
USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION 
Your privacy is important to us. During this study, we will ask you to share identifiable health 
information with us. This health information is Protected Health Information, so it will be 
protected like your other medical records are protected. We are asking you to authorize the 
release of your research information in the specific situations described below:   
 
Types of Personal Health Information That May Be Collected by This Study  
The following types of information may be used to conduct this research study: 
 Complete health record  Diagnosis & treatment codes  Discharge summary 
 History and physical exam  Consultation reports  Progress notes 
 Laboratory test results  X-ray reports  X-ray films / images 
 Photographs, videotapes Complete billing record  Itemized bill 
 Information about drug or alcohol abuse  Information about Hepatitis B or C tests 
 Information about psychiatric care  Information about sexually transmitted 
diseases 
 Other (specify):  medical and psychiatric conditions, current medications, symptoms of PCS, self 
reported levels of stress and depression, and salivary cortisol.      
 
Expiration of This Authorization   
 This authorization will expire when the research study is closed, or there is no need to review, analyze and 
consider the data generated by the research project, whichever is later. 
 This research study involves the use of a Data or Tissue Repository (bank) and will never expire. 
  Other (specify):        
 
Authority to Request or Release Protected Health Information 
The following people and/or groups may request my Protected Health Information and the 
Principal Investigator may release my information to them: 
 Health Care Providers at the VCUHS     Study Sponsor     
 Research Collaborators and Study Staff     Institutional Review Boards    
 Data Safety Monitoring Boards     Government/Health Agencies   
 Data Coordinators  Others as Required by Law 
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Once your health information has been disclosed to anyone outside of this study, the information 
may no longer be protected under this authorization. 
 
Right to Revoke Authorization and Re-disclosure 
You may change your mind and revoke (take back) the right to use your Protected Health 
Information at any time.  Even if you revoke this Authorization, the researchers may still use or 
disclose health information they have already collected about you for this study. If you revoke 
this Authorization you may no longer be allowed to participate in the research study.  To revoke 
this Authorization, you must write to the Principal Investigator. 
 
COSTS 
There are no costs for participating in this study other than the time you will spend filling out 
questionnaires.  
 
PAYMENT FOR PARTICIPATION 
Upon conclusion of the second study visit, when we have collected the saliva sample from you, 
you will be given a $10 Walmart gift card as compensation for your time. 
 
ALTERNATIVES 
The alternative to participating in this study is to not participate. 
 
CONFIDENTIALITY 
Potentially identifiable information about you will consist of the study questionnaires.   
Your data will be de-identified by the assignment of an ID number, not names, and stored 
separately from research data in a locked research area. All personal identifying information will 
be kept in password protected files and these files will be deleted within 7 years of study 
completion.  Other records, such as the screening forms and questionnaires, will be kept in a 
locked file cabinet in the research offices of VCU School of Nursing for 7 years after the study 
ends and will be destroyed at that time.  Access to all data will be limited to study personnel.  
We will not tell anyone the answers you give us; however, information from the study and the 
consent form signed by you may be looked at or copied for research or legal purposes by 
Virginia Commonwealth University.  Personal information about you might be shared with or 
copied by authorized officials of the Department of Health and Human Services or other federal 
regulatory bodies.  
If something we learn through this research indicates that you may intend to harm yourself or 
others, we are obligated to report that to the appropriate authorities.   
What we find from this study may be presented at meetings or published in papers, but your 
name will not ever be used in these presentations or papers. 
 
VOLUNTARY PARTICIPATION AND WITHDRAWAL 
Your participation in this study is voluntary.  You may decide to not participate in this study.  
Your decision not to take part will involve no penalty or loss of benefits to which you are 
otherwise entitled.  If you do participate, you may freely withdraw from the study at any time. 
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Your decision to withdraw will involve no penalty or loss of benefits to which you are otherwise 
entitled. 
 
Your participation in this study may be stopped at any time by the study staff without your 
consent. The reasons might include: 
 the study staff thinks it necessary for your health or safety; 
 you have not followed study instructions; 
 the sponsor has stopped the study; or 
 administrative reasons require your withdrawal. 
 
QUESTIONS 
If you have any questions, complaints, or concerns about your participation in this research, 
contact: 
 
 Victoria Menzies, PhD, RN, PMHCNS-BC, FAAN 
Associate Professor 
P.O. Box 980567 
Richmond, VA 23298-0567 
Phone: (804) 628-3381 
E-mail: vsmenzies@vcu.edu 
 
     and/or 
 
Christine Huson, MSN, RN 
Student Investigator 
101 Elm Ave, SE 
Roanoke, VA  24013-2222 
Phone: (540) 985-4028 
 E-mail: husonc@vcu.edu 
 
The researcher/study staff named above is the best person(s) to call for questions about your 
participation in this study.  
 
If you have any general questions about your rights as a participant in this or any other research, 
you may contact: 
 
 Office of Research 
 Virginia Commonwealth University 
 800 East Leigh Street, Suite 3000 
 P.O. Box 980568 
 Richmond, VA  23298 
 Telephone: (804) 827-2157 
 
Contact this number to ask general questions, to obtain information or offer input, and to express 
concerns or complaints about research. You may also call this number if you cannot reach the 
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research team or if you wish to talk with someone else.  General information about participation 
in research studies can also be found at  
http://www.research.vcu.edu/human_research/volunteers.htm. 
 
 
CONSENT 
 
I have been given the chance to read this consent form. I understand the information about this 
study. Questions that I wanted to ask about the study have been answered. My signature says 
that I am willing to participate in this study.  I will receive a copy of the consent form once I 
have agreed to participate. 
  
 
 
Participant name printed   Participant signature  Date 
 
 
________________________________________________ 
Name of Person Conducting Informed Consent Discussion 
(Printed) 
 
 
________________________________________________________________________ 
Signature of Person Conducting Informed Consent Discussion Date 
 
 
________________________________________________________________________ 
Principal Investigator Signature (if different from above)   Date  
 
 
 
 
This study is an initial exploration of relationships among stress, cortisol and depression. Study 
findings have the potential to provide a foundation for a future intervention study.  
 
If you are interested in being contacted for future studies, we ask your permission to contact you. 
If you agree to be contacted, we ask the method of contact you prefer. 
 
This permission to be contacted for future studies can be withdrawn at any time by contacting the 
following researchers: 
Victoria Menzies, PhD, RN, PMHCNS-BC, FAAN 
Associate Professor 
P.O. Box 980567 
Richmond, VA 23298-0567 
Phone: (804) 628-3381 
E-mail: vsmenzies@vcu.edu 
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and/or 
Christine Huson, MSN, RN 
Student Investigator 
101 Elm Ave, SE 
Roanoke, VA  24013-2222 
Phone: (540) 985-4028 
 E-mail: husonc@vcu.edu 
The decision to not be contacted for future studies does not affect your ability to participate in 
this current study. 
_______ No, I do not wish to be contacted for future studies. 
 
_______Yes, I would like to be contacted for future studies. My preferred contact information is: 
 
_____________________________________________________________________________ 
 
 
If yes, Participant name printed   Participant signature  Date 
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Stand Alone HIPAA Form 
Title of Document:  
“Authorization to Use or Disclose (Release) Health Information that Identifies You for a 
Research Study” 
 
Victoria Menzies, PhD, RN, PMHCNS-BC, FAAN                             Christine Huson, MSN, RN 
Associate Professor                                                                                Student Investigator 
P.O. Box 980567                                                                                    101 Elm Ave, SE 
Richmond, VA 23298-0567                                                                   Roanoke, VA  24013-2222 
Phone: (804) 628-3381                                      Phone: (540) 985-4028 
E-mail: vsmenzies@vcu.edu                                             E-mail: husonc@vcu.edu                     
 
Date: 
 
RE: IRB Protocol #HM20009108 
 
Dear Potential Study Participant: 
 
If you sign this document, you give permission for the student investigator to confirm your 
diagnosis of PCS through communication with your healthcare provider,  
_____________________________________________________ (M.D.) (D. O.) (N.P.) (P.A.) at  
_____________________________________________________ 
_____________________________________________________ 
_____________________________________________________ 
 
Your signature authorizes the student investigator to use or disclose (release) your health 
information that 
identifies you for the research study described below:  
 
Perceived Stress, Salivary Cortisol and Depression in Adults with Postconcussion 
Syndrome; A Pilot Study 
 
This study is being conducted to learn more about the relationship between perceived stress; 
cortisol, a hormone related to stress; and symptoms such as distressed mood that might occur 
among individuals with a diagnosis of PCS. 
 
The health information that we may use or disclose (release) for this research includes 
information that you have a confirmed diagnosis of postconcussion syndrome.  
 
Address line 1 
Address line 2 
Telephone Number 
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The health information listed above may be used by and/or disclosed (released) to: Dr. Victoria 
Menzies, Principal Investigator.     
 
 
 
_____________________________________ (M.D.) (D.O.) (N.P.) (P.A.) is required by law to 
protect your health information.  
 
By signing this document, you authorize ____________________________________, (M.D.) 
(D.O.) (N.P.) (P.A.) to disclose (release) your health information for this research.  
 
Those persons who receive your health information may not be required by Federal privacy laws 
(such as the Privacy Rule) to protect it and may share your information with others without your 
permission, if permitted by laws governing them.    
 
Please note that: 
 You do not have to sign this Authorization, but if you do not, you may not be eligible to 
participate in this study 
 You may change your mind and revoke (take back) this Authorization at any time, except to 
the extent that ___________________ (M.D.) (D.O.) (N.P.) (P.A.) has already acted based 
on this Authorization.  
To revoke this Authorization, you must write to: Victoria S. Menzies PhD, RN, FAAN, 
1100 East Leigh Street, P.O. Box 980567 Richmond, VA  23298-0567 
 Your health information will be used or disclosed when required by law. 
 Your health information may be shared with a public health authority that is authorized by 
law to collect or receive such information for the purpose of preventing or controlling 
disease, injury, or disability, and conducting public health surveillance, investigations or 
interventions. 
 No publication or public presentation about the research described above will reveal your 
identity. 
 If all information that does or can identify you is removed from your health information, the 
remaining information will no longer be subject to this authorization and may be used or 
disclosed for other purposes. 
 
This Authorization does not have an expiration date. 
 
______________________________________________________________________________       
Printed name of participant     Signature of participant 
 
_________________________ 
                       Date 
Sincerely, 
 
Victoria Menzies, PhD, RN, FAAN 
Associate Professor   
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Diagnosis Confirmation Note 
Victoria Menzies, PhD, RN, FAAN                                                    Christine Huson, MSN, RN 
Associate Professor                                                                              Student Investigator 
P.O. Box 980567                                                                                  101 Elm Ave, S.E. 
Richmond, VA 23298-0567                                                                  Roanoke, VA 24013-2222 
Phone: (804) 628-3381                                                                          Phone: (540) 985-4028 
E-mail: vsmenzies@vcu.edu                                                                 E-mail: husonc@vcu.edu 
Date: 
(Healthcare Provider Name) 
(Address) 
(City State Zip) 
 
Re:  Request from your patient (patient’s name), regarding IRB Protocol #HM20009108 
Dear <<HCP >> 
We are conducting a study titled, “Perceived Stress, Salivary Cortisol and Depression in Adults 
with Postconcussion Syndrome; A Pilot Study”. 
Your patient, (<<patient’s name>>), has volunteered for this study, if (<<she/he>>) meets the 
inclusion criteria.  One criterion for inclusion is a confirmed diagnosis of postconcussion 
syndrome from the patient’s healthcare provider. Attached is a HIPAA-approved signed 
authorization letter from <<patient name>>, requesting that you confirm, for study purposes, 
(<<her/his>>) diagnosis of postconcussion syndrome. 
Would you please complete and sign the information below?  You may return it to the Principal 
Investigator, at Virginia Commonwealth University School of Nursing at the HIPAA approved 
confidential fax number (804) 828-2487.  Thank you. 
Sincerely, 
 
Victoria Menzies, PhD, RN, FAAN 
 
Patient’s Name: _____________________________________________________________ 
 
Diagnosis: _____________________________________________________________ 
 
Date of Diagnosis: _____________________________________________________________ 
 
 
 
Healthcare provider’s Signature: 
_____________________________________________________________      
 
Today’s Date: 
___________________________________________________________________________ 
 
133 
 
 
Appendix F  
1. Demographic Form and Medical History 
2. Rivermead Post Concussion Symptoms Questionnaire 
3. Perceived Stress Scale 
4. Center for Epidemiologic Studies Depression Scale 
5. PROMIS Emotional Distress Depression Short Form 
6. Salivary Cortisol Instruction 
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Demographic Form and Medical History 
Stress, cortisol and depression in Adults with PCS                               Subject ID: 
 
                                                                                                                 Time:                               : 
                                                                   
Demographic Form                                                                     
Directions: Please complete the following information. 
1. Age:  _________ 
2. What is your ethnicity? 
 Hispanic or Latino ________ 
 Not-Hispanic or Latino _______ 
3. What is your race? 
 American Indian or Alaska Native _______ 
 Asian ________ 
  Native Hawaiian or Other Pacific Islander _______ 
 Hispanic or Latino _________ 
 White ________ 
 Do not wish to answer _________ 
4. Current Relationship Status: 
 Living with a partner ________ 
 Married ________ 
 Single, and never been married _________ 
 Divorced/Separated _______ 
 Widow/Widower _________ 
5. What date did your head injury occur? 
 _ _/_ _/ _ _ _ _ 
6. What date were you diagnosed with Postconcussive Syndrome? 
 _ _/_ _/_ _ _ _ (month/day/year) j 
7. Please select your household income level 
 Less than $14,000 ______ 
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 $14,000 – 24,999 _______ 
 $25, 000 -34,999 _______ 
 $35,000 -49.000 _______ 
 50.000 or more   _______ 
  
8. Please list any medical and/or psychiatric illness that you have experienced (such as heart 
disease, diabetes, depression). 
____________________________________________________________________________ 
____________________________________________________________________________ 
 ____________________________________________________________________________ 
 
 
Please fill out your medication information on the following page: 
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Please list current medications you are taking as well as dietary supplements and/or herbal 
products. 
 
NAME 
of product or 
medication 
DOSAGE 
 (if known) 
FREQUENCY 
How often do 
you take it? 
PRESCRIPTION 
began when? 
PURPOSE 
For what symptoms 
are you taking this 
product or 
medication?  
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Rivermead Post Concussion Symptoms Questionnaire 
SID:_____________        Date:___________ 
 
The Rivermead Post-Concussion Symptoms Questionnaire 
 
After a head injury or accident some people experience symptoms which can cause worry or 
nuisance. We would like to know if you now suffer from any of the symptoms given below. 
As many of these symptoms occur normally, we would like you to compare yourself now with 
before the accident. For each one, please circle the number closest to your answer. 
 
0 = Not experienced at all 
1 = No more of a problem 
2 = A mild problem 
3 = A moderate problem 
4 = A severe problem 
 
Compared with before the accident, do you now (i.e., over the last 24 hours) suffer from: 
 
Headaches....................................................................... 0   1   2   3   4 
Feelings of Dizziness...................................................... 0   1   2   3   4 
Nausea and/or Vomiting ........................... …………….0   1   2   3   4 
Noise Sensitivity, easily upset by loud noise ..................0   1   2   3   4 
Sleep Disturbance ...........................................................0   1   2   3   4 
Fatigue, tiring more easily ............................................. 0   1   2   3   4 
Being Irritable, easily angered ....................................... 0   1   2   3   4 
Feeling Depressed or Tearful.........................................  0   1   2   3   4 
Feeling Frustrated or Impatient......................................  0   1   2   3   4 
Forgetfulness, poor memory ..................... ……………..0   1   2   3   4 
Poor Concentration...........................................................0   1   2   3   4 
Taking Longer to Think .................................................  0   1   2   3   4 
Blurred Vision ................................................................  0   1   2   3   4 
Light Sensitivity, Easily upset by bright light ................  0   1   2   3   4 
Double Vision.................................................................   0   1   2   3   4 
Restlessness ..................................................................... 0   1   2   3   4 
 
Are you experiencing any other difficulties? 
 
1. _______________________________ 0   1   2   3   4 
 
2. _______________________________ 0   1   2   3   4 
 
 
 
 
 
 
138 
 
 
Perceived Stress Scale 
SID:_______________       Date____________ 
Perceived Stress Scale 
The questions in this scale ask you about your feelings and thoughts during the last month. In 
each case, you will be asked to indicate by circling how often you felt or thought a certain way. 
 
0 = Never  
1 = Almost Never  
2 = Sometimes  
3 = Fairly Often  
4 = Very Often 
 
1. In the last month, how often have you been upset 
because of something that happened unexpectedly?...................................... 0  1  2  3  4 
 
2. In the last month, how often have you felt that you were unable 
to control the important things in your life? .................................................. 0  1  2  3  4 
 
3. In the last month, how often have you felt nervous and “stressed”? ...........0  1  2  3  4 
 
4. In the last month, how often have you felt confident about your ability 
to handle your personal problems? .................................................................. 0  1  2  3  4 
 
5. In the last month, how often have you felt that things 
were going your way?...................................................................................... 0  1  2  3  4 
 
6. In the last month, how often have you found that you could not cope 
with all the things that you had to do? ............................................................ 0  1  2  3  4 
 
7. In the last month, how often have you been able 
to control irritations in your life?..................................................................... 0  1  2  3  4 
 
8. In the last month, how often have you felt that you were on top of things?. 0  1  2  3  4 
 
9. In the last month, how often have you been angered 
because of things that were outside of your control?................................... ….0  1  2  3  4 
 
10. In the last month, how often have you felt difficulties 
were piling up so high that you could not overcome them? ............................ 0  1  2  3  4 
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Center for Epidemiologic Studies Depression Scale 
 Rarely or 
none of the 
time         
(less than 1 
day) 
Some or a 
little of the 
time          
(1-2 days) 
Occasionally 
or a moderate 
amount of the 
time              
(3-4 days) 
Most or all 
of the time 
(5-7 days) 
During the past week:     
1) I was bothered by things that 
usually don’t bother me 
0 1 2 3 
2) I did not feel like eating; my 
appetite was poor 
0 1 2 3 
3) I felt that I could not shake off 
the blues even with help from my 
family and friends 
0 1 2 3 
4) I felt that I was just as good as 
other people 
0 1 2 3 
5) I had trouble keeping my mind 
on what I was doing 
0 1 2 3 
6) I felt depressed 0 1 2 3 
7) I felt that everything I did was 
an effort 
0 1 2 3 
8) I felt hopeful about the future 0 1 2 3 
9) I thought my life had been a 
failure 
0 1 2 3 
10) I felt fearful 0 1 2 3 
11) My sleep was restless 0 1 2 3 
12) I was happy 0 1 2 3 
13) I talked less than usual 0 1 2 3 
14) I felt lonely 0 1 2 3 
15) People were unfriendly 0 1 2 3 
16) I enjoyed life 0 1 2 3 
17) I had crying spells 0 1 2 3 
18) I felt sad 0 1 2 3 
19) I felt that people disliked me 0 1 2 3 
20) I could not get “going” 0 1 2 3 
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PROMIS Emotional Distress Depression Short Form 
 
 
PROMIS Item Bank v1.0 – Emotional Distress – Depression–Short Form 8a 
 
Emotional Distress – Depression – Short Form 8a 
 
Please respond to each question or statement by marking one box per row. 
 
 
 
  In the past 7 days...      
   Never Rarely Sometimes Often Always 
EDDEP04 1 
I felt worthless ............................................ 
1 

2 

3 

4 

5 
       
EDDEP06 2 
I felt helpless .............................................. 
1 

2 

3 

4 

5 
       
EDDEP29 3 
I felt depressed ........................................... 
1 

2 

3 

4 

5 
       
EDDEP41 4 
I felt hopeless ............................................. 
1 

2 

3 

4 

5 
       
EDDEP22 5 
I felt like a failure ....................................... 
1 

2 

3 

4 

5 
       
EDDEP36 6 
I felt unhappy ............................................. 
1 

2 

3 

4 

5 
       
EDDEP05 7 
I felt that I had nothing to look forward to . 
1 

2 

3 

4 

5 
       
EDDEP09 8 
I felt that nothing could cheer me up.......... 
1 

2 

3 

4 

5 
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Salivary Cortisol Instructions 
Salivary Cortisol Sampling Instructions 
Before Sample Collection  
• Avoid foods with high sugar or acidity, immediately before sample collection; 
• Document consumption of alcohol, caffeine, nicotine, and prescription/over-the-counter 
medications 
  within the prior 12 hours.  
• Avoid steroid-based anti-inflammatory medications.  
• Document vigorous physical activity and the presence of oral diseases or injury.  
• Do not eat a major meal within 60 minutes of sample collection.  
• Rinse mouth with water to remove food residue and wait at least 10 minutes after rinsing to  
avoid sample dilution before collecting saliva.  
 
How to collect the sample 
 Remove SOS from outer packaging and place in mouth.  
 Keep SOS in place for 1-2 minutes to ensure that it is saturated (Do not move around in the 
mouth).  
 Place SOS into the swab storage basket insert (upper portion of the tube).   
 Replace cap and snap securely onto tube.  
 
 After Sample Collection  
• Record the time and date of collection.  
• Freeze samples immediately  
• Samples visibly contaminated with blood should be recollected. Notify student investigator to 
obtain new kit.  
 
 
 
 
